CF
MCID: CYS001
MIFTS: 83

Cystic Fibrosis (CF) malady

Categories: Genetic diseases, Rare diseases, Metabolic diseases, Gastrointestinal diseases, Liver diseases, Reproductive diseases, Respiratory diseases, Endocrine diseases

Aliases & Classifications for Cystic Fibrosis

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 35LifeMap Discovery®, 37MedGen, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Cystic Fibrosis:

Name: Cystic Fibrosis 52 35 11 71 48 24 25 54 70 27 12 50 38 39 13 68
Mucoviscidosis 11 48 24 25 54 70
Pseudomonas Aeruginosa Chronic Infection by, in Cystic Fibrosis 52
 
Cystic Fibrosis Lung Disease, Modifier of 52
Fibrocystic Disease of Pancreas 25
Cystic Fibrosis of Pancreas 25

Characteristics:

Orphanet epidemiological data:

54
cystic fibrosis:
Inheritance: Autosomal recessive; Age of onset: All ages; Age of death: adult,young Adult

HPO:

64
cystic fibrosis:
Inheritance: autosomal recessive inheritance

Classifications:



External Ids:

OMIM52 219700
Disease Ontology11 DOID:1485
ICD1030 E84, E84.9
ICD9CM32 277.0
MeSH39 D003550
NCIt45 C2975
Orphanet54 ORPHA586
ICD10 via Orphanet31 E84.0, E84.1, E84.8 E84.9, more
MESH via Orphanet40 D003550
UMLS via Orphanet69 C0010674
MedGen37 C0010674

Summaries for Cystic Fibrosis

About this section
MedlinePlus:38 Cystic fibrosis (cf) is an inherited disease of the mucus and sweat glands. it affects mostly your lungs, pancreas, liver, intestines, sinuses, and sex organs. cf causes your mucus to be thick and sticky. the mucus clogs the lungs, causing breathing problems and making it easy for bacteria to grow. this can lead to repeated lung infections and lung damage. the symptoms and severity of cf can vary. some people have serious problems from birth. others have a milder version of the disease that doesn't show up until they are teens or young adults. sometimes you will have few symptoms, but later you may have more symptoms. cf is diagnosed through various tests, such as gene, blood, and sweat tests. there is no cure for cf, but treatments have improved greatly in recent years. in the past, most deaths from cf were in children and teenagers. today, with improved treatments, some people who have cf are living into their forties, fifties, or older. treatments may include chest physical therapy, nutritional and respiratory therapies, medicines, and exercise. nih: national heart, lung, and blood institute

MalaCards based summary: Cystic Fibrosis, also known as CF, is related to cystic fibrosis with helicobacter pylori gastritis, megaloblastic anemia, and mental retardation and cystic fibrosis and congenital absence of the vas deferens, and has symptoms including coughing, coughing and hemoptysis. An important gene associated with Cystic Fibrosis is CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), and among its related pathways are Cytokine production by Th17 cells in CF (Mouse model) and Regulation of degradation of deltaF508 CFTR in CF. The drugs acetylcysteine and sodium phenylbutyrate have been mentioned in the context of this disorder. Affiliated tissues include lung, pancreas and testes, and related mouse phenotype mortality/aging.

Disease Ontology:11 An autosomal recessive disease that is characterized by the buildup of thick, sticky mucus that can damage many organs.

Genetics Home Reference:25 Cystic fibrosis is an inherited disease characterized by the buildup of thick, sticky mucus that can damage many of the body's organs. The disorder's most common signs and symptoms include progressive damage to the respiratory system and chronic digestive system problems. The features of the disorder and their severity varies among affected individuals.

NIH Rare Diseases:48 Cystic fibrosis (cf) is an inherited condition that causes mucus to build up and clog some of the organs in the body, particularly in the lungs and pancreas. when mucus clogs the lungs, it can make breathing very difficult. the thick mucus also causes bacteria to get stuck in the airways, which causes inflammation and infections. these infections can cause chronic coughing, and wheezing. over time, mucus buildup and infections can lead to permanent lung damage, including the formation of scar tissue (fibrosis) and cysts in the lungs. mucus can also block the digestive tract and pancreas, leading to digestive problems. cf is caused by mutations in the cftr gene and is inherited in an autosomal recessive pattern. last updated: 4/4/2013

OMIM:52 Formerly known as cystic fibrosis of the pancreas, this entity has increasingly been labeled simply 'cystic fibrosis.'... (219700) more...

UniProtKB/Swiss-Prot:70 Cystic fibrosis: A common generalized disorder of the exocrine glands which impairs clearance of secretions in a variety of organs. It is characterized by the triad of chronic bronchopulmonary disease (with recurrent respiratory infections), pancreatic insufficiency (which leads to malabsorption and growth retardation) and elevated sweat electrolytes. It is the most common genetic disease in Caucasians, with a prevalence of about 1 in 2'000 live births. Inheritance is autosomal recessive.

Wikipedia:71 Cystic fibrosis (CF) is a genetic disorder that affects mostly the lungs, but also the pancreas, liver,... more...

Related Diseases for Cystic Fibrosis

About this section

Diseases related to Cystic Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 342)
idRelated DiseaseScoreTop Affiliating Genes
1cystic fibrosis with helicobacter pylori gastritis, megaloblastic anemia, and mental retardation12.1
2cystic fibrosis and congenital absence of the vas deferens11.9
3follicular hamartoma-alopecia-cystic fibrosis syndrome11.9
4bronchiectasis with or without elevated sweat chloride 211.6
5bronchiectasis with or without elevated sweat chloride 111.5
6bronchiectasis with or without elevated sweat chloride 311.5
7congenital bilateral absence of vas deferens11.4
8allergic bronchopulmonary aspergillosis11.4
9meconium ileus11.4
10bronchiectasis11.3
11pancreatitis11.3
12aspergillosis11.3
13exocrine pancreatic insufficiency11.2
14stenotrophomonas maltophilia infection11.1
15shwachman-diamond syndrome11.1
16respiratory failure11.1
17keratomalacia11.1
18nontuberculous mycobacterial lung disease11.1
19lubani-al saleh-teebi syndrome11.1
20aquagenic syringeal acrokeratoderm10.9
21spinal muscular atrophy-110.8
22spinal muscular atrophy-210.8
23pseudohypoaldosteronism, type i10.8
24middle lobe syndrome10.8
25young syndrome10.8
26pancreatic ductal adenocarcinoma10.6
27lung disease10.5
28subcorneal pustular dermatosis10.4CFTR, CXCL8, ELANE, IFRD1, TGFB1
29acute chest syndrome10.4CFTR, CXCL8, ELANE, TGFB1
30chitotriosidase deficiency10.4CFTR, TGFB1
31coq7-related coenzyme q10 deficiency10.4CFTR, TGFB1
32fasciitis10.4CFTR, CXCL8, ELANE
33primary congenital glaucoma10.4CFTR, PRSS1, SPINK1
34familial renal papillary carcinoma10.4CFTR, CXCL8, ELANE
35malignant neoplasm of acoustic nerve10.4CXCL8, ELANE, TGFB1
36myxofibrosarcoma10.4CFTR, PRSS1, SPINK1
37netherton syndrome10.4CFTR, ELANE, PRSS1, SPINK1
38cervical adenomyoma10.4CFTR, PRSS1, SPINK1
39thyroid gland disease10.4CFTR, ELANE, PRSS1, SPINK1
40spontaneous ocular nystagmus10.4CXCL8, ELANE, TGFB1
41avoidant personality disorder10.4CFTR, CXCL8, PLCZ1
42ritscher-schinzel syndrome 110.3CXCL8, S100A9
43lacrimal system cancer10.3CXCL8, ELANE, SPINK1
44fibrosis of extraocular muscles, congenital, 3c10.3CFTR, SPINK1
45mycobacterium abscessus10.3
46liver disease10.2
47alcoholic hepatitis10.2
48chromophobe renal cell carcinoma10.2
49renal oncocytoma10.2
50bone fracture10.2CLCA1, CLCA4

Graphical network of the top 20 diseases related to Cystic Fibrosis:



Diseases related to cystic fibrosis

Symptoms & Phenotypes for Cystic Fibrosis

About this section

Symptoms by clinical synopsis from OMIM:

219700

Clinical features from OMIM:

219700

Human phenotypes related to Cystic Fibrosis:

 54 64 (show all 21)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 exocrine pancreatic insufficiency64 54 Very frequent (99-80%) HP:0001738
2 malabsorption64 54 Very frequent (99-80%) HP:0002024
3 recurrent respiratory infections64 54 Very frequent (99-80%) HP:0002205
4 pulmonary fibrosis64 54 Very frequent (99-80%) HP:0002206
5 hepatomegaly64 54 Occasional (29-5%) HP:0002240
6 biliary cirrhosis64 54 Very frequent (99-80%) HP:0002613
7 immunodeficiency64 54 Very frequent (99-80%) HP:0002721
8 decreased antibody level in blood64 54 Very frequent (99-80%) HP:0004313
9 failure to thrive64 HP:0001508
10 cor pulmonale64 HP:0001648
11 dehydration64 HP:0001944
12 rectal prolapse64 HP:0002035
13 asthma64 HP:0002099
14 bronchiectasis64 HP:0002110
15 hypercalciuria64 HP:0002150
16 male infertility64 HP:0003251
17 meconium ileus64 HP:0004401
18 chronic lung disease64 HP:0006528
19 recurrent pneumonia64 HP:0006532
20 recurrent bronchopulmonary infections64 HP:0006538
21 elevated sweat chloride64 HP:0012236

UMLS symptoms related to Cystic Fibrosis:


coughing, hemoptysis, snoring

MGI Mouse Phenotypes related to Cystic Fibrosis according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:001076810.2CFTR, DERL1, DNAJC5, DNASE1, ELANE, FCGR2A

Drugs & Therapeutics for Cystic Fibrosis

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Cayston16 AZTREONAM Gilead February 2010
FDA Label: Cayston
Disease/s that Drug Treats:cystic fibrosis patients with Pseudomonas aeruginosa
Indications and Usage:16 CAYSTON is a monobactam antibacterial indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia. (1)
DrugBank Targets:14 Penicillin-binding protein 3|Beta-lactamase
Mechanism of Action:16 
Target: penicillin binding proteins of susceptible bacteria
Action: inhibition of bacterial cell wall synthesis
FDA: Aztreonam is an antibacterial drug [see Clinical Pharmacology (12.4)]. Aztreonam exhibits activity in vitro against Gram-negative aerobic pathogens including P. aeruginosa. Aztreonam binds to penicillinbinding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis and death of the cell. Aztreonam activity is not decreased in the presence of CF lung secretions.
2
Kalydeco16 IVACAFTOR Vertex Pharmaceuticals January of 2012
FDA Label: Kalydeco
Disease/s that Drug Treats:cystic fibrosis with the G551D mutation in the CFTR gene
Indications and Usage:16 KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. KALYDECO is indicated for the treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (1) Limitations of Use: * Not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene. (1, 14)
DrugBank Targets:14 Cystic fibrosis transmembrane conductance regulator
Mechanism of Action:16 
Target: cystic fibrosis transmembrane conductance regulator (CFTR)
Action: potentiator
FDA: Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein. In vitro, ivacaftor increased CFTR-mediated transepithelial current (IT) in rodent cells expressing the G551D-CFTR protein following addition of a cyclic adenosine monophosphate (cAMP) agonist with an EC50 of 100 ± 47 nM; however, ivacaftor did not increase IT in the absence of cAMP agonist. Ivacaftor also increased IT in human bronchial epithelial cells expressing G551D-CFTR protein following addition of a cAMP agonist by 10-fold with an EC50 of 236 ± 200 nM. Ivacaftor increased the open probability of G551D-CFTR protein in single channel patch clamp experiments using membrane patches from rodent cells expressing G551D-CFTR protein by 6-fold versus untreated cells after addition of PKA and ATP. In addition to G551D-CFTR, ivacaftor increased the channel-open probability of other mutant CFTR forms expressed in rodent cells, resulting in enhanced CFTR-mediated IT. These mutant CFTR forms included G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-, S1251N-, S1255P-, and G1349D-CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has low channel-open probability (gating) and reduced channel current amplitude (conductance) compared to normal CFTR. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.
3
Orkambi16 IVACAFTOR; LUMACAFTOR Vertex Pharmaceuticals July 2015
FDA Label: Orkambi
Disease/s that Drug Treats:cystic fibrosis
Indications and Usage:16 ORKAMBI is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. (1) Limitations of Use: The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation. (1)
DrugBank Targets:14 Cystic fibrosis transmembrane conductance regulator
Mechanism of Action:16 
Target: cystic fibrosis transmembrane conductance regulator (CFTR)
Action: oral regulators
FDA: The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. The F508del mutation results in protein misfolding, causing a defect in cellular processing and trafficking that targets the protein for degradation and therefore reduces the quantity of CFTR at the cell surface. The small amount of F508del-CFTR that reaches the cell surface is less stable and has low channel-open probability (defective gating activity) compared to wild-type CFTR protein. Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein at the cell surface. In vitro studies have demonstrated that both lumacaftor and ivacaftor act directly on the CFTR protein in primary human bronchial epithelial cultures and other cell lines harboring the F508del-CFTR mutation to increase the quantity, stability, and function of F508del-CFTR at the cell surface, resulting in increased chloride ion transport. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.
4
Pulmozyme16 DORNASE ALFA Genentech December 1996| March 1998
FDA Label: Pulmozyme
Disease/s that Drug Treats:cystic fibrosis
Indications and Usage:16 PULMOZYME is a recombinant DNase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. (1)
DrugBank Targets:14 DNA
Mechanism of Action:16 
Target: -
Action: -
FDA: PULMOZYME is recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. In preclinical in vitro studies, PULMOZYME hydrolyzes the DNA in sputum of CF patients and reduces sputum viscoelasticity. In CF patients, retention of viscous purulent secretions in the airways contributes both to reduced pulmonary function and to exacerbations of infection. Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to infection.
5
Tobi16 TOBRAMYCIN PathoGenesis December 1997
FDA Label: Tobi
Disease/s that Drug Treats:cystic fibrosis
Indications and Usage:16 TOBI is indicated for the management of cystic fibrosis patients with P. aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) <25% or >75% predicted, or patients colonized with Burkholderia cepacia (see CLINICAL STUDIES).
DrugBank Targets:14 30S ribosomal protein S12|16S rRNA
Mechanism of Action:16 
Target: -
Action: -
FDA: Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. (1) It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death.(3) Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. It is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.

Drugs for Cystic Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 460)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Acetylcysteineapproved, investigationalPhase 4, Phase 2, Phase 1330616-91-112035
Synonyms:
(2R)-2-acetylamino-3-sulfanylpropanoic acid
(R)-2-acetylamino-3-mercaptopropanoic acid
(R)-mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
Fluprowit
 
L-Acetylcysteine
L-acetylcysteine
L-α-acetamido-β-mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetyl-L-(+)-cysteine
N-acetyl-L-cysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
2
Mycophenolic acidapprovedPhase 4, Phase 395224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
3
AzithromycinapprovedPhase 4, Phase 3, Phase 2, Phase 134683905-01-555185, 53477736, 447043
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-,(2R-(2R*,3S*
121470-24-4
75199_FLUKA
83905-01-5
9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A
AC-16014
AC1L9KEG
Aritromicina
Azasite
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
Azithromycin
Azithromycin & Tumor Necrosis Factor
Azithromycin (AIDS Initiative)
Azithromycin (anhydrous)
Azithromycin Dihydrate
Azithromycin Monohydrate
Azithromycin Sterile
Azithromycin dihydrate
Azithromycin plus Tumor Necrosis Factor
Azithromycine
Azithromycine [French]
Azithromycinum
Azithromycinum [Latin]
Azitrocin
Azitromax
Azitromicina
Azitromicina [Spanish]
Azitromin
Azythromycin
BIDD:GT0792
BRN 5387583
BSPBio_002285
Bio-0676
C38H72N2O12
CCRIS 1961
CHEBI:2955
CHEMBL529
CID447043
CP-62993
CP62,993
CPD000471864
DCH3
DRG-0104
 
DivK1c_000233
HMS1922G12
HMS2094M11
HMS500L15
HSDB 7205
Hemomycin
IDI1_000233
KBio1_000233
KBio2_000787
KBio2_003355
KBio2_005923
KBio3_001505
KBioGR_000731
KBioSS_000787
LS-1834
MLS001055353
MLS001066331
MLS001201763
MLS001304005
MLS001332499
MLS001332500
Misultina
MolPort-002-507-426
N,N-Dimethyl-4-amino-benzaldehyde
NCGC00090753-01
NCGC00090753-02
NINDS_000233
NSC643732
SAM002589961
SMR000471864
SPBio_001544
SPECTRUM1503679
Spectrum2_001582
Spectrum3_000653
Spectrum4_000186
Spectrum5_001867
Spectrum_000307
Sumamed
Tromix
UNII-JTE4MNN1MD
XZ-450
Z-Pak
ZIT
Zentavion
Zithromac
Zithromax
Zithromax IV
Zithromycin
Zitromax
Zitromax Avium 600
Zmas
Zmax
azithromycin
4
Insulin GlargineapprovedPhase 4, Phase 3528160337-95-1
Synonyms:
 
Insulin Glargine (rDNA origin)
Insulin glargine recombinant
5
Tobramycinapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 212032986-56-45496, 36294
Synonyms:
1-Epitobramycin
11098-01-4
11111-45-8
3'-Deoxykanamycin B
3'-Deoxykanamycin b
32986-56-4
34337-51-4
37321-13-4
49842-07-1 (Sulfate)
54330-95-9
70322-33-7
79645-27-5
A 12253A
AB00513858
AC1L1KGY
AC1L1VI0
AC1O7GFJ
AC1Q2AOW
AKOS000715235
Aktob
BAS 00463364
BIDD:GT0503
BPBio1_000647
BRN 1357507
BSPBio_000587
BSPBio_002036
Brulamycin
C00397
C18H37N5O9
CAS-32986-56-4
CHEBI:28864
CHEBI:533587
CHEMBL1747
CID11340303
CID36294
CID5496
CID6604388
CID9804613
CID9934285
CPD000058793
D00063
DB00684
Deoxykanamycin B
Distobram
EINECS 251-322-5
Gotabiotic
HMS1569N09
HMS2090B16
HMS2092M17
HSDB 3259
KBio2_001552
KBio2_004120
KBio2_006688
KBio3_001536
KBioGR_001104
KBioSS_001552
LS-146940
LS-187329
Lilly 47663
MLS000069544
MolPort-001-934-131
MolPort-003-665-548
MolPort-003-939-629
NCGC00016814-01
NCGC00178852-01
NCGC00178852-02
NEBRAMYCIN
NF 6
NSC 180514
 
NSC180514
Nebcin
Nebcin (Sulfate)
Nebicin
Nebramycin 6
Nebramycin VI
Nebramycin factir 6
Nebramycin factor 6
Nebramycin-Faktor 6
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Obracin
Obramycin
Prestwick0_000544
Prestwick1_000544
Prestwick2_000544
Prestwick3_000544
Prestwick_850
S2514_Selleck
SAM001246911
SMR000058793
SPBio_000295
SPBio_002508
SPECTRUM1500579
SPRC-AB01
STK182610
Spectrum2_000078
Spectrum3_000588
Spectrum4_000752
Spectrum5_001038
Spectrum_001072
Sybryx
T4014_SIGMA
TOA-(1-6)2TB-(4-1)TOC
TOA-(1-6)TOB-(4-1)TOC
TOBRAMYCIN SULFATE
TOY
Tenebrimycin
Tenemycin
Tobacin
Tobi
Tobracin
Tobracin (TN)
Tobracin (tn)
Tobradex
Tobradistin
Tobralex
Tobramaxin
Tobramicin
Tobramicina
Tobramicina [INN-Spanish]
Tobramitsetin
Tobramycetin
Tobramycin
Tobramycin (JP15/USP)
Tobramycin Sulfate
Tobramycin [USAN:BAN:INN:JAN]
Tobramycin for Inhalation
Tobramycin solution for inhalation
Tobramycin, Free Base
Tobramycine
Tobramycine [INN-French]
Tobramycinum
Tobramycinum [INN-Latin]
Tobrased
Tobrasone
Tobrex
Tobrex (TN)
Tobrex (tn)
UNII-VZ8RRZ51VK
tobramycin
tobramycin solution for inhalation
6
Mycophenolate mofetilapproved, investigationalPhase 4, Phase 3952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
7
CeftazidimeapprovedPhase 4, Phase 16578439-06-25481173
Synonyms:
(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
72558-82-8
7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
AB00513848
AC1L1E5K
AC1L3MNA
AC1NUK7U
AC1NUN9Q
BIDD:GT0734
BRN 4344904
C06889
C2225
C22H22N6O7S2
CAZ
CEFTAZIDIME (ARGININE FORMULATION)
CHEBI:3508
CHEMBL201
CID2650
CID5481173
CID5484131
 
Ceftazidim
Ceftazidima
Ceftazidima [INN-Spanish]
Ceftazidime
Ceftazidime (INN)
Ceftazidime (TN)
Ceftazidime Sodium In Plastic Container
Ceftazidime anhydrous
Ceftazidime pentahydrate
Ceftazidimum
Ceftazidimum [INN-Latin]
Ceptaz
Ceptaz (TN)
D07654
DB00438
EINECS 276-715-9
Fortaz
Fortaz (TN)
Fortaz In Plastic Container
HMS2090M13
I06-1102
LS-132194
SN 401
UNII-9M416Z9QNR
ceftazidima
ceftazidime
ceftazidimum
8
Meropenemapproved, investigationalPhase 497119478-56-764778, 441130
Synonyms:
(1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate
(1R,5S,6S)-2-[(3S,5S)-5-DIMETHYLAMINOCARBONYLPYRROLIDIN-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid
(2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid
(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
96036-03-2
AB00514051
AB1004614
AC1L9ALL
Ambap119478-56-7
Antibiotic SM 7338
Antibiotic sm 7338
BIDD:GT0851
BPBio1_001334
BSPBio_001212
CHEBI:43968
CHEMBL127
CID441130
CPD000469184
D08185
HMS1571M14
HMS2051G08
HMS2090C05
 
ICI-194660
MEPM
MERONEM
MLS001401437
Meronem (TN)
Meropen
Meropenem
Meropenem (INN)
Meropenem Hydrate
Meropenem anhydrous
Meropenem trihydrate
Meropenemum
Meropenemum [INN-Latin]
Meropenemum trihydricum
Merrem
Merrem I.V. (TN)
MolPort-006-709-417
NCGC00179259-01
Prestwick0_001106
Prestwick1_001106
Prestwick2_001106
Prestwick3_001106
SAM001246650
SM-7338
SMR000469184
SPBio_003086
9
MentholapprovedPhase 4, Phase 3, Phase 126062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
10
AztreonamapprovedPhase 4, Phase 3, Phase 24878110-38-05362041, 5742832
Synonyms:
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid
2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
78110-38-0
AC-4330
AC1NX3U2
AZT
Ambap78110-38-0
Azactam
Aztreonam
Aztreonamum
Aztréonam
BIDD:GT0765
BPBio1_000121
BRD-K62607865-001-03-0
 
BSPBio_000109
CHEBI:161680
CHEMBL158
CID5742832
HMS1568F11
HMS2090K09
MolPort-003-886-345
Monobactam, SQ 26776, Squibb 26776, Aztreonam
NCGC00179656-01
NSC646279
Prestwick2_000185
Prestwick3_000185
Prestwick_914
Primbactam
S1505_Selleck
SQ-26776
[2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid
aztreonam
11
Doxycyclineapproved, investigational, vet_approvedPhase 4, Phase 2243564-25-054671203
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
5-hydroxy-α-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6alpha-deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Alti-Doxycycline
Anhydrous doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline (200mg/day) or Placebo
 
Doxycycline (INN)
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
12
TamoxifenapprovedPhase 439010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
13
AltretamineapprovedPhase 4, Phase 165645-05-62123
Synonyms:
2,4, 6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylami
2,4,6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylamino)-S-triazine
2,4,6-Tris(dimethylamino)-s-triazine
2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
549835_ALDRICH
645-05-6
A 8723
A0567/0026158
A8723_SIGMA
AB00052308
AC-12006
AC1L1CYX
AI3-50852
AKOS001729401
Altretamin
Altretamina
Altretamina [INN-Spanish]
Altretamine (USP/INN)
Altretamine Bellon Brand
Altretamine Chiesi Brand
Altretamine Wassermann Brand
Altretamine [USAN:INN:BAN]
Altretaminum
Altretaminum [INN-Latin]
Altrétamine
BPBio1_001004
BRD-K67043667-001-04-1
BRN 0195058
BSPBio_000912
Bellon Brand of Altretamine
C9H18N6
CAS-654-05-6
CCRIS 5492
CHEBI:24564
CHEMBL1455
CID2123
CPD000058181
ChemDiv2_005185
Chiesi Brand of Altretamine
D006585
D02841
DB00488
DivK1c_000772
EINECS 211-428-4
ENT 50852
EU-0100083
FT-0083576
HEXAMETHYLMELAMINE
HMM
HMS1383L15
HMS1570N14
HMS1922C05
HMS2090G17
HMS2092H16
HMS502G14
HSDB 7559
HTM
HXM
Hemel
Hexalen
Hexalen (TN)
Hexalen, Altretamine
 
Hexamethylmelamine
Hexastat
Hexinawas
I06-0604
IDI1_000772
IDI1_003900
InChI=1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H
KB-913
KBio1_000772
KBio2_001788
KBio2_004356
KBio2_006924
KBio3_002042
KBioGR_001388
KBioSS_001788
LS-1549
Lopac-A-8723
Lopac0_000083
MGI Pharma Brand of Altretamine
MLS000069621
MLS001076123
MolPort-002-111-210
N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine
NC 195
NCGC00015100-01
NCGC00015100-02
NCGC00015100-03
NCGC00015100-06
NCGC00015100-11
NCGC00021216-03
NCGC00021216-04
NCGC00021216-05
NCGC00021216-06
NCGC00021216-07
NCI-C50259
NCI60_000871
NINDS_000772
NSC 13875
NSC-13875
NSC13875
N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine
Prestwick0_000946
Prestwick1_000946
Prestwick2_000946
Prestwick3_000946
Rhone Poulenc Rorer Brand of Altretamine
Rhone-Poulenc Rorer Brand of Altretamine
S1278_Selleck
SAM002564241
SMR000058181
SPBio_000754
SPBio_003071
SPECTRUM1503065
ST086739
STK749184
Spectrum2_000907
Spectrum3_000951
Spectrum4_001064
Spectrum5_001092
Spectrum_001308
UNII-Q8BIH59O7H
WLN: T6N CN ENJ BN1&1 DN1&1 FN1&1
Wassermann Brand of Altretamine
ZINC00000905
altretamine
no)-s-triazine
14
PancrelipaseapprovedPhase 4, Phase 3, Phase 297053608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
15
Itraconazoleapproved, investigationalPhase 4, Phase 2, Phase 115884625-61-655283
Synonyms:
(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one
(+/-)-1-[( R *)- sec -butyl]-4-[ p -[4-[ p -[[(2 R *,4 S *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-(DELTA) 2 1,2,4-triazolin-5-one mixture with (+/-)-1-[( R *)- sec -butyl]-4-[ p -[4- [ p -[[(2 S *,4 R *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl] phenyl]-(DELTA) 2 -1,2,4-triazolin-5-one
(1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one
2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)
4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
84604-65-9
84625-61-6
AC-542
AC1L1GQ5
AC1L1IRU
AC1OCEL7
AC1Q6EZ3
AKOS000280875
Ambap84625-61-6
BIDD:GT0796
BRN 6042047
C35H38Cl2N8O4
CHEBI:6076
CHEMBL22587
CHEMBL882
CID3793
CID55283
CID6917738
CID9961741
CPD000058959
Canadiol
D00350
DB01167
EINECS 283-347-2
FT-0082511
HMS2051K14
HMS2090M20
Hyphanox
I01-1043
I0732
ITC
ITCZ
ITZ
Intraconazole
 
Itraconazol
Itraconazol [Spanish]
Itraconazole
Itraconazole & Bovine Lactoferrin
Itraconazole & Nyotran
Itraconazole & Nyotran(Liposomal Nystatin)
Itraconazole (JAN/USAN)
Itraconazole [USAN:BAN:INN:JAN]
Itraconazole oral solution
Itraconazolum
Itraconazolum [Latin]
Itrizole
Itrizole (TN)
Itrizole (tn)
LS-1843
MLS000028582
MLS000759472
MLS000863291
MLS001148245
MolPort-000-883-864
MolPort-003-848-295
NCGC00089812-03
Oriconazole
Oriconazole, R51211, Sporanox
Orungal
Prokanazol
R 51211
R-51211
S2476_Selleck
SAM001246679
SMR000058959
Sempera
Spherazole
Sporal
Sporanos
Sporanox
Sporanox (TN)
Sporanox (tn)
Sporonox
TL8005525
Triasporn
UNII-304NUG5GF4
cis-Itraconazole
itraconazole
16
NicotineapprovedPhase 4110354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
17
ColistinapprovedPhase 4, Phase 2, Phase 1641264-72-8, 1066-17-75311054
Synonyms:
1066-17-7
AC1NSJWT
CID5311054
Colistin
Colistin sulfate, nonsterile
Colistin sulphate
 
Colistina
Colistine
Colistinum
DB00803
N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-5-methylheptanamide
Polymyxin E
Polymyxin E. Sulfate
colistin
18AvibactamapprovedPhase 4261192500-31-4
19
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
20
AlendronateapprovedPhase 4, Phase 3162121268-17-5, 66376-36-12088
Synonyms:
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-hydroxybutylidene)bisphosphonic acid
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
4-amino-1-hydroxybutane-1,1-diphosphonic acid
66376-36-1
ABDP
AC1L1CW3
AKOS001015793
ALENDRONATE SODIUM
ALENDRONIC ACID
Acide Alendronique
Acide Alendronique [INN-French]
Acide alendronique
Acide alendronique [INN-French]
Acido Alendronico
Acido Alendronico [INN-Spanish]
Acido alendronico
Acido alendronico [INN-Spanish]
Acidum Alendronicum
Acidum Alendronicum [INN-Latin]
Acidum alendronicum
Acidum alendronicum [INN-Latin]
Adronat
 
Alendronate
Alendronate Sodium
Alendronate sodium hydrate
Alendronic acid
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Arendal
BIDD:GT0180
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
alendronate
bisphosphonate, 65
21
TazobactamapprovedPhase 410389786-04-9123630
Synonyms:
(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4
(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
89785-84-2
89786-04-9
AC-7620
AC1L3X07
BIDD:GT0212
C07771
CHEBI:100207
CHEMBL404
 
CID123630
CL-298741
CL298741
D00660
DB01606
MolPort-002-500-123
TAZ
Tazobactam
Tazobactam (JAN/USAN/INN)
YTR-830H
YTR830H
22
RifampinapprovedPhase 4, Phase 2, Phase 134813292-46-15458213, 5381226
Synonyms:
1-b]furan-21-yl acetate
13292-46-1
3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin
3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV
3-(4-Methylpiperazinyliminomethyl)-rifamycin SV
3-(4-Methylpiperazinyliminomethyl)rifamycin SV
3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV
3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV
3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin
46713_FLUKA
46713_RIEDEL
62534-43-4
8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV
8-(4-Methylpiperazinyliminomethyl) rifamycin SV
8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin
8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv
8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv
83907_FLUKA
83907_SIGMA
8CI)
AZT + Rifampin
Abrifam
Archidyn
Arficin
Arzide
BA-41166E
BIDD:PXR0014
BPBio1_000561
BSPBio_000509
Ba 41166
Ba 41166/E
Benemicin
Benemycin
Bio-0621
C06688
C43H58N4O12
CAS-13292-46-1
CCRIS 551
CHEBI:28077
CHEBI:455936
CHEMBL180
CID5381226
CID5388984
CID5458213
CID5702112
CID6604339
CID6708473
CID6842115
CID6912767
CID6913622
CPD001906767
D00211
DB01045
DRG-0109
Dione 21-acetate
Dipicin
DivK1c_000550
Doloresum
EINECS 236-312-0
Eremfat
Famcin
Fenampicin
HMS1569J11
HMS1920P08
HMS2089F12
HMS2092G09
HMS501L12
HSDB 3181
KBio1_000550
KBio2_000919
KBio2_003487
KBio2_006055
KBio3_003018
KBioGR_001780
KBioSS_000919
L-5103
L-5103 Lepetit
LS-7689
MLS000028552
MLS001148237
MLS001333745
MolPort-000-767-051
MolPort-002-513-586
MolPort-003-666-281
MolPort-006-395-891
NCGC00016699-01
NCGC00017365-01
NCGC00018178-01
NCGC00022678-03
NCGC00022678-04
NCGC00022678-05
NCGC00160500-01
 
NCI60_000309
NINDS_000550
NSC 113926
NSC-113926
NSC113926
Piperine & Rifampicin
Prestwick0_000525
Prestwick1_000525
Prestwick2_000525
Prestwick3_000525
Prestwick_833
R-Cin
R/AMP
R0079
R3501_SIAL
R3501_SIGMA
R5777_SIGMA
R7382_SIGMA
RAMP
RFP
RMP
Ramp
Reserpine & Rifampicin
Rf
Rfamipicin
Rifa
Rifadin
Rifadin (TN)
Rifadin I.V
Rifadin I.V.
Rifadin IV
Rifadin Iv
Rifadin, Rimactane, Rifampicin, Rifampin
Rifadine
Rifagen
Rifaldazin
Rifaldazine
Rifaldin
Rifam
Rifamicin AMP
Rifamor
Rifampicin
Rifampicin & EEP
Rifampicin & Propolis
Rifampicin (JP15/INN)
Rifampicin SV
Rifampicin [INN:BAN:JAN]
Rifampicina
Rifampicina [INN-Spanish]
Rifampicine
Rifampicine [French]
Rifampicinum
Rifampicinum [INN-Latin]
Rifampin
Rifampin (USP)
Rifampin [USAN]
Rifamsolin
Rifamycin
Rifamycin AMP
Rifamycin Amp
Rifaprodin
Rifcin
Rifinah
Rifobac
Rifoldin
Rifoldine
Riforal
Rimactan
Rimactane
Rimactane (TN)
Rimactazid
Rimactin
Rimactizid
Rimazid
Rimycin
Rofact
S1764_Selleck
SAM002264646
SMR000058322
SMR000653525
SPBio_002430
SPECTRUM1500529
STK080143
Sinerdol
Spectrum3_001837
Spectrum4_001250
Spectrum5_002018
Spectrum_000439
TNP00313
Tubocin
UNII-VJT6J7R4TR
WLN: V1 WQ A&1 E&1 E1UN- AT6N DNTJ D1
nchembio884-comp4
rifampin
23
Ciprofloxacinapproved, investigationalPhase 4, Phase 2, Phase 123685721-33-12764
Synonyms:
1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
17850_FLUKA
3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)
33434_FLUKA
33434_RIEDEL
85721-33-1
AC-7613
AC1L1EEW
AKOS000269653
ARONIS020379
Alcon Cilox
BAS 06989041
BAY q 3939
BAY-Q-3939
BAYQ3939
BIDD:GT0205
BPBio1_000140
BRD-K04804440-311-02-3
BRN 3568352
BSPBio_000126
BSPBio_003344
Bacquinor
Baflox
Bay o 9867
Bay o 9867 (*Hydrochloride*)
Bay-09867
Baycip
Bernoflox
Bi-Cipro
Bio-0540
C05349
C17H18FN3O3
CAS-93107-08-5
CBMicro_048498
CCRIS 5241
CHEBI:100241
CHEMBL8
CID2764
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
CPF
CPFX
CRL-1605 & Ciprofloxacin
Ciflox
Cifloxin
Cilab
Ciloxan
Ciloxan (*Hydrochloride*)
Ciplus
Ciprecu
Ciprinol
Cipro
Cipro (*Hydrochloride*)
Cipro (TN)
Cipro I.V.
Cipro IV
Cipro XL
Cipro XR
Ciprobay
Ciprobay Uro
Ciprocinol
Ciprodar
Ciproflox
Ciprofloxacin (JAN/USP/INN)
Ciprofloxacin HCl
Ciprofloxacin Hydrchloride
Ciprofloxacin [USAN:INN:BAN]
Ciprofloxacin dihydrochloride
Ciprofloxacin hydrochloride
Ciprofloxacin monohydrochloride
Ciprofloxacina
Ciprofloxacine
Ciprofloxacine [INN-French]
Ciprofloxacino
Ciprofloxacino [INN-Spanish]
Ciprofloxacinum
 
Ciprofloxacinum [INN-Latin]
Ciprogis
Ciprolin
Ciprolon
Cipromycin
Ciproquinol
Ciprowin
Ciproxan
Ciproxin
Ciproxina
Ciproxine
Ciriax
Citopcin
Cixan
Corsacin
Cycin
Cyprobay
D00186
DB00537
DivK1c_000095
Eni
Fimoflox
Flociprin
Floxin
HMS1922E18
HMS2090O07
HMS2093I03
HMS500E17
HSDB 6987
IDI1_000095
Ipiflox
Italnik
KBio1_000095
KBio2_000642
KBio2_003210
KBio2_005778
KBio3_002846
KBioGR_001567
KBioSS_000642
LS-141563
Liposomal-ciprofloxacin
Loxan
MLS001336035
MolPort-000-819-654
NCGC00016959-01
NCGC00095058-01
NCGC00095058-02
NCGC00178128-01
NINDS_000095
NSC620634
Ocuflox
Oprea1_008239
Oprea1_313572
Prestwick0_000113
Prestwick1_000113
Prestwick2_000113
Prestwick3_000113
Probiox
Proflaxin
Proflox
Proksi 250
Proksi 500
Proquin XR
Quinolid
Quintor
Rancif
Roxytal
SMP1_000125
SMR000471901
SPBio_001474
SPBio_002065
SPECTRUM1503614
STK021082
Septicide
Sophixin Ofteno
Spectrum2_001567
Spectrum3_001872
Spectrum4_000874
Spectrum5_001089
Spectrum_000162
Spitacin
Superocin
UNII-5E8K9I0O4U
Unex
Velomonit
Zumaflox
ciprofloxacin
nchembio820-comp1
24
Ticarcillinapproved, vet_approvedPhase 41034787-01-436921
Synonyms:
(2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-thiophen-3-ylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
17778_FLUKA
34787-01-4
6beta-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-2,2-dimethylpenam-3alpha-carboxylic acid
AC1L1WMX
AC1Q5QWE
BRL-2288
C07139
C15H16N2O6S2
CHEBI:9587
CHEMBL1449
CID36921
D08593
DB01607
EINECS 252-213-5
LS-174491
MolPort-003-927-225
Prestwick0_001067
Prestwick1_001067
 
Prestwick2_001067
SPBio_002967
TICARCILLIN
TIPC
Ticarcilina
Ticarcilina [INN-Spanish]
Ticarcilina [inn-spanish]
Ticarcillin (INN)
Ticarcillin Supplement
Ticarcillin [INN:BAN]
Ticarcillin supplement
Ticarcilline
Ticarcilline [INN-French]
Ticarcilline [inn-french]
Ticarcillinum
Ticarcillinum [INN-Latin]
Ticarcillinum [inn-latin]
Ticillin [veterinary]
Ticillin [veterinary] (TN)
UNII-F93UJX4SWT
a-carboxy-3-thienylmethylpenicillin
alpha-Carboxy-3-thienylmethylpenicillin
alpha-carboxy-3-thienylmethylpenicillin
25
PiperacillinapprovedPhase 410166258-76-243672
Synonyms:
(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
4-ethyl-2,3-dioxopiperazine carbonyl ampicillin
59703-84-3
59703-84-3 (mono-hydrochloride salt)
6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid
61477-96-1
6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
AC1L2ACR
AC1Q5QXJ
BIDD:GT0167
BPBio1_000848
BRD-K86873305-236-03-0
BSPBio_000770
C14034
C23H27N5O7S
CCRIS 7362
CHEBI:8232
CHEMBL702
CID43672
Cl-227193
D08380
EINECS 262-811-8
HMS2090H19
LS-149794
 
PIPC
PIPERACILLIN SODIUM
Peperacillin
Peracin
Peracin (TN)
Piperacilina
Piperacillin
Piperacillin (INN)
Piperacillin (anhydrous)
Piperacillin Anhydrous
Piperacillin Monosodium Salt
Piperacillin anhydrous
Piperacillina
Piperacillinum
Pipercillin
Pipracil
Pipracil, Piper
Pipril
Pipéracilline
Prestwick0_000755
Prestwick1_000755
Prestwick2_000755
Prestwick3_000755
SPBio_002709
T-1220
UNII-9I628532GX
piperacillin
26
FosfomycinapprovedPhase 4, Phase 23423155-02-4446987
Synonyms:
(−
(-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid
(1R,2S)(-)-(1,2-Epoxypropyl)phosphonic acid disodium salt
(1R,2S)-Epoxypropylphosphonic acid
(1R,2S)-epoxypropylphosphonate
(1R,2S)-epoxypropylphosphonic acid
(2R-cis)-(3-Methyloxiranyl)phosphonic acid
(2R-cis)-(3-Methyloxiranyl)phosphonic acid disodium salt
)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid
1R-cis-(1,2-Epoxypropyl)phosphonic acid
23155-02-4
26016-99-9
34089_FLUKA
34089_RIEDEL
6F066DFF-696A-4A94-AF78-A28430EBE5BA
AC1L2JXY
AC1L9KC0
AC1Q1URS
AR-1I6648
BIDD:GT0448
BRN 1680831, Fosfocina
C06454
CHEBI:681859
CHEMBL1757
CID446987
CID73491
CPD0-1113
D02188
D04253
DB00828
Disodium (1R,2S)-(1,2-epoxypropyl)phosphonate
Disodium fosfomycin
Disodium phosphonomycin
EINECS 247-409-2
FCM
FOM-Na
FOSFOMYCIN
 
Fosfocina
Fosfocina disodium salt
Fosfomicina
Fosfomycin (USAN/INN)
Fosfomycin disodium
Fosfomycin disodium salt
Fosfomycin sodium
Fosfomycin sodium (JP15)
Fosfomycin sodium salt
Fosfomycine
Fosfomycinum
Fosfonomycin
Fosmicin S
Fosmicin S (TN)
I06-1211
L-cis-1,2-Epoxypropylphosphonic acid
L-cis-1,2-epoxypropylphosphonic acid
LS-106593
MK 955
MolPort-003-847-502
NSC 136017
P5396_SIGMA
Phosphomycin
Phosphomycin disodium salt
Phosphonemycin
Phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2R-cis)- (9CI)
Phosphonomycin
Phosphonomycin disodium salt
Phosphonomycin sodium
Priomicina
Sodium fosfomycin
Veramina
ZINC19594585
[(2R,3S)-3-methyloxiran-2-yl]phosphonic acid
cis-(1R,2S)-Epoxypropylphosphonic acid
disodium[(2r,3s)-3-methyloxiran-2-yl]phosphonate
nchem.1024-comp6
phosphomycin
27
CefepimeapprovedPhase 43888040-23-75479537
Synonyms:
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime)
7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
88040-23-7
AC1NUIFH
Axepim
BMY 28142
BMY-28142
C08111
C19H24N6O5S2
CFPM
CHEBI:478164
CHEMBL186
CID5479537
Cefepima
Cefepima [Spanish]
 
Cefepima [spanish]
Cefepime
Cefepime (USAN/INN)
Cefepime [USAN:INN]
Cefepimum
Cefepimum [Latin]
Cefepimum [latin]
Cepimax
Cepimex
D02376
DB01413
HMS2089M18
LS-178033
Maxcef
Maxipime
UNII-807PW4VQE3
ZINC03871924
cefepime
28
Omalizumabapproved, investigationalPhase 4145242138-07-4
Synonyms:
242138-07-4
D05251
Ig gamma-1 chain C region
Omalizumab
 
Omalizumab (USAN/INN)
Omalizumab (genetical recombination)
Omalizumab (genetical recombination) (JAN)
Xolair
Xolair (TN)
29
Tacrolimusapproved, investigationalPhase 41102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
30
Posaconazoleapproved, investigational, vet_approvedPhase 456171228-49-2147912
Synonyms:
1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
171228-49-2
177571-33-4
4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
AC-1350
AC1L3W34
AC1LAHLQ
AKOS005145917
CHEBI:434337
CHEMBL1397
CHEMBL371938
CHEMBL371939
CID10532764
CID11520437
CID11542142
CID147912
CID468595
D02555
 
DB01263
HSDB 7421
LS-186118
LS-186988
LS-187630
MolPort-006-666-426
Noxafil
Noxafil (TN)
Noxafil, Posaconazole
Posaconazole
Posaconazole (USAN/INN)
Posaconazole SP
Posaconazole [USAN:INN:BAN]
Posaconazole in combination with MGCD290
S1257_Selleck
SCH-56592
SCH56592
Sch 56592
Spriafil
UNII-6TK1G07BHZ
X2N
posaconazole
31
Cholecalciferolapproved, nutraceuticalPhase 4, Phase 3, Phase 2, Phase 187567-97-06221, 10883523, 5280795
Synonyms:
()-Vitamin D3
(+)-Vitamin D3
(+)-vitamin D3
(1S,3Z)-3-[(2e)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol
47763_SUPELCO
57651-82-8
67-97-0
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
9,10-Secocholesta-5,7,10(19)-trien-3-ol
9,10-Secocholesta-5,7,10-trien-3-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
Activated 7-dehydrocholesterol
Arachitol
BPBio1_000460
BSPBio_000418
BSPBio_002408
Bio-0845
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
CID7067440
CID7251172
CID7251174
CID9821465
Calciol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol D3
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferolum
Colecalciferol
 
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Devaron
DivK1c_006276
Duphafral D3 1000
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
Ebivit
FeraCol
Granuvit D3
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC-375571
NSC375571
Oleovitamin D3
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Prestwick_63
Provitamine
Provitina
Quintox
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SR-05000001559
SR-05000001559-3
ST057172
SpecPlus_000180
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
Spectrum_001163
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
VITAMIN D
VITAMIN D3 POWDER
VITAMIN_D3
Vi-De3
Vi-de-3-hydrosol
VidDe-3-hydrosol
Videkhol
Vigantol
Vigorsan
Vitamin D-3
Vitamin D3
Vitamin D3 emulsifiable
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
bmse000507
cholecalciferol
colecalciferolum
vitamin d-3
32
Ergocalciferolapproved, nutraceuticalPhase 4, Phase 3, Phase 2, Phase 1128150-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
33Hypoglycemic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15896
34Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 18402
35insulinPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14646
36Lipid Regulating AgentsPhase 4, Phase 2, Phase 12766
37Hypolipidemic AgentsPhase 4, Phase 2, Phase 12785
38Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
39Immunosuppressive AgentsPhase 4, Phase 313086
40Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 111226
41Antirheumatic AgentsPhase 4, Phase 3, Phase 1, Phase 210956
42AntimetabolitesPhase 4, Phase 2, Phase 112054
43AnalgesicsPhase 4, Phase 3, Phase 2, Phase 111733
44Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 16501
45Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110729
46Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 3, Phase 1, Phase 24443
47Insulin, Globin ZincPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14645
48Calcium, DietaryPhase 4, Phase 35713
49Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 18192
50Cytochrome P-450 Enzyme InhibitorsPhase 4, Phase 3, Phase 2, Phase 13917

Interventional clinical trials:

(show top 50)    (show all 967)
idNameStatusNCT IDPhase
1Impact of Immunonutrition on the Patients With Cystic FibrosisUnknown statusNCT02048592Phase 4
2Duration of Antibiotics in Infective Exacerbations of Cystic FibrosisUnknown statusNCT01044719Phase 4
3The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal SymptomsUnknown statusNCT00866866Phase 4
4Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung PerfusionUnknown statusNCT01353105Phase 4
5Backpack Carrying in Children With Cystic FibrosisCompletedNCT02700282Phase 4
6Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza VaccinationCompletedNCT01499914Phase 4
7Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic FibrosisCompletedNCT01983787Phase 4
8Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic FibrosisCompletedNCT01608555Phase 4
9RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis SputumCompletedNCT00843817Phase 4
10Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic FibrosisCompletedNCT01400750Phase 4
11Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic FibrosisCompletedNCT01377792Phase 4
12Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic FibrosisCompletedNCT00528190Phase 4
13Should Any One Airway Clearance Technique be Recommended for People With Cystic Fibrosis?CompletedNCT00890370Phase 4
14Circadian Rhythm In Tobramycin Elimination In Cystic FibrosisCompletedNCT01207245Phase 4
15The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic FibrosisCompletedNCT00557089Phase 4
16Effect of Lactobacillus Reuteri in Cystic FibrosisCompletedNCT01737983Phase 4
17Comparison of Absorption of Vitamin D in Cystic FibrosisCompletedNCT01880346Phase 4
18Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. AeruginosaCompletedNCT00431964Phase 4
19Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different SettingsCompletedNCT00685035Phase 4
20Doxycycline Effects on Inflammation in Cystic FibrosisCompletedNCT01323101Phase 4
21A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic FibrosisCompletedNCT01712334Phase 4
22Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic FibrosisCompletedNCT01519661Phase 4
23Scandinavian Cystic Fibrosis Azithromycin StudyCompletedNCT00411736Phase 4
24Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic InsufficiencyCompletedNCT01327703Phase 4
25Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) ChildrenCompletedNCT01429259Phase 4
26Cystic Fibrosis and Totally Implantable Vascular Access DevicesCompletedNCT00244270Phase 4
27Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis PatientsCompletedNCT00157690Phase 4
28Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)CompletedNCT01844778Phase 4
29Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis PatientsCompletedNCT02178540Phase 4
30Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis PatientsCompletedNCT02421120Phase 4
31One Year Glargine Treatment in CFRD Children and AdolescentsCompletedNCT00483769Phase 4
32Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic FibrosisCompletedNCT02504827Phase 4
33PR-018: An Open-Label, Safety Extension of Study PR-011CompletedNCT01131507Phase 4
34A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of AgeCompletedNCT01100606Phase 4
35Malabsorption Blood Test:Toward a Novel Approach to Quantify SteatorrheaCompletedNCT00572975Phase 4
36Electro Flo 5000 and Vest TherapyCompletedNCT02277626Phase 4
37Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished ChildrenCompletedNCT02128984Phase 4
38Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular DystrophyCompletedNCT01882400Phase 4
39Ext. Long-term Safety Study in CF Patients: Single Arm TIPCompletedNCT01775137Phase 4
40Effectiveness and Safety of Inhaling Hypertonic Saline in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00639236Phase 4
41Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast CancerCompletedNCT00999921Phase 4
42Pharmacokinetics of Tedizolid Phosphate in Cystic FibrosisRecruitingNCT02444234Phase 4
43Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic FibrosisRecruitingNCT02894684Phase 4
44EASY: Extended Access to Sollpura Over YearsRecruitingNCT02823964Phase 4
45Standardized Treatment of Pulmonary Exacerbations IIRecruitingNCT02781610Phase 4
46Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With CFRecruitingNCT02677701Phase 4
47Effects of a Partially Supervised Conditioning Program in CFRecruitingNCT01744561Phase 4
48A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR MutationRecruitingNCT02823470Phase 4
49IV Colistin for Pulmonary Exacerbations: Improving Safety and EfficacyRecruitingNCT02918409Phase 4
50A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie CapsuleRecruitingNCT02929420Phase 4

Search NIH Clinical Center for Cystic Fibrosis

Inferred drug relations via UMLS68/NDF-RT46:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cystic Fibrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cystic Fibrosis:
Mesenchymal stem cells for cystic fibrosis
Embryonic/Adult Cultured Cells Related to Cystic Fibrosis:
Mouse bone marrow-derived mesenchymal stem cells (family), PMIDs: 21658631, 20801416


Cochrane evidence based reviews: cystic fibrosis

Genetic Tests for Cystic Fibrosis

About this section

Genetic tests related to Cystic Fibrosis:

id Genetic test Affiliating Genes
1 Cystic Fibrosis27 24 CFTR

Anatomical Context for Cystic Fibrosis

About this section

MalaCards organs/tissues related to Cystic Fibrosis:

36
Lung, Pancreas, Testes, Liver, Neutrophil, Colon, Bone

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cystic Fibrosis:
id TissueAnatomical CompartmentCell Relevance
1 LungRespiratory BronchiolesBasal Cells Potential therapeutic candidate
2 LungRespiratory BronchiolesCilliated Cells Potential therapeutic candidate, affected by disease
3 LungSubmucosal Glands  Affected by disease

Publications for Cystic Fibrosis

About this section

Articles related to Cystic Fibrosis:

(show top 50)    (show all 3783)
idTitleAuthorsYear
1
Microbial Dysbiosis in Bronchiectasis and Cystic Fibrosis. (28069292)
2017
2
Six-Minute Walk Test Results Predict Risk of Hospitalization for Youths with Cystic Fibrosis: A 5-Year Follow-Up Study. (28087053)
2017
3
In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. (28068001)
2017
4
End-stage cystic fibrosis lung disease is characterised by a diverse inflammatory pattern: an immunohistochemical analysis. (28069067)
2017
5
sTREM-1 is elevated in cystic fibrosis and correlates with proteases. (28068000)
2017
6
Does newborn screening influence the young cystic fibrosis cohort included in national registries? (28077474)
2017
7
EIT based pulsatile impedance monitoring during spontaneous breathing in cystic fibrosis. (28530203)
2017
8
Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation. (28079883)
2017
9
Clostridium difficile infection in cystic fibrosis: an uncommon but life-threatening complication. (28078087)
2017
10
Serum Albumin and Disease Severity of Non-Cystic Fibrosis Bronchiectasis. (28512120)
2017
11
Airway Clearance Techniques for Primary Ciliary Dyskinesia; is the Cystic Fibrosis literature portable? (28408202)
2017
12
Two Small Molecules Restore Stability to a Sub-population of the Cystic Fibrosis Transmembrane conductance Regulator with the Predominant Disease-causing Mutation. (28087700)
2017
13
Lung function imaging methods in Cystic Fibrosis pulmonary disease. (28514950)
2017
14
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. (28090087)
2017
15
Factors influencing the need for endoscopic sinus surgery in adult patients with cystic fibrosis. (28234153)
2017
16
Distal intestinal obstruction syndrome and colonic pathologies in cystic fibrosis. (28067560)
2017
17
Draft genome sequence of an aminoglycoside-resistant RmtG-producing Pseudomonas aeruginosa ST235 isolated from a cystic fibrosis patient. (28082143)
2017
18
Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic. (28091521)
2017
19
Genomic information on multidrug-resistant livestock-associated methicillin-resistant Staphylococcus aureus ST398 isolated from a Brazilian patient with cystic fibrosis. (28076471)
2017
20
Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough? (28077615)
2017
21
Diagnosis of bronchiectasis and airway wall thickening in children with cystic fibrosis: Objective airway-artery quantification. (28523349)
2017
22
Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. (27717223)
2017
23
Body composition and lung function in children with cystic fibrosis and meconium ileus. (28409283)
2017
24
Effects of treadmill exercise versus FlutterAr on respiratory flow and sputum properties in adults with cystic fibrosis: a randomised, controlled, cross-over trial. (28077104)
2017
25
Early Lung Function Decline in Cystic Fibrosis: Can Registry Data Explain Divergent Phenotypes? (28504907)
2017
26
Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus. (28508992)
2017
27
Scedosporium apiospermum complex in cystic fibrosis; should we treat? (28504471)
2017
28
Direct measurement of trafficking of the cystic fibrosis transmembrane conductance regulator to the cell surface and binding to a chemical chaperone. (28001373)
2017
29
Investigating the feasibility of text message reminders to improve adherence to nebulized medication in children and adolescents with cystic fibrosis. (28507430)
2017
30
The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis. (28508087)
2017
31
Multidrug-resistant Mycobacterium abscessus threatens patients with cystic fibrosis. (27956215)
2017
32
Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: MR Imaging of Airway Mucus Contrasts as a Tool for Diagnosis. (28530849)
2017
33
Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways. (28516246)
2017
34
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis. (28499793)
2017
35
Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection. (28505188)
2017
36
Increasing Total Serum IgE, Allergic Bronchopulmonary Aspergillosis, and Lung Function in Cystic Fibrosis. (28526275)
2017
37
Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis. (28529073)
2017
38
Lung structure and function similarities between primary ciliary dyskinesia and mild cystic fibrosis: a pilot study. (28403885)
2017
39
Cystic fibrosis carriership and tuberculosis: hints toward an evolutionary selective advantage based on data from the Brazilian territory. (28499359)
2017
40
Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients. (28526799)
2017
41
Role of IRE1I+/XBP-1 in Cystic Fibrosis Airway Inflammation. (28075361)
2017
42
Successful outcome following pneumonectomy in a teenage boy with cystic fibrosis: a case report. (28086849)
2017
43
Aspergillus fumigatus in cystic fibrosis: an update on immune interactions and molecular diagnostics in ABPA. (28513848)
2017
44
Two cases of non-cystic fibrosis (CF) bronchiectasis with allergic bronchopulmonary aspergillosis. (28053855)
2017
45
Body Sanctification and Sleep in Adolescents with Cystic Fibrosis: A Pilot Study. (28516396)
2017
46
Cystic fibrosis transmembrane conductance regulator mediates tenogenic differentiation of tendon-derived stem cells and tendon repair: accelerating tendon injury healing by intervening in its downstream signaling. (28495756)
2017
47
Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. (26585435)
2016
48
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis. (27664282)
2016
49
Benign and Deleterious Cystic Fibrosis Transmembrane Conductance Regulator Mutations Identified by Sequencing in Positive Cystic Fibrosis Newborn Screen Children from California. (27214204)
2016
50
Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor. (27659740)
2016

Variations for Cystic Fibrosis

About this section

UniProtKB/Swiss-Prot genetic disease variations for Cystic Fibrosis:

70 (show all 133)
id Symbol AA change Variation ID SNP ID
1CFTRp.Ser13PheVAR_000101rs397508635
2CFTRp.Arg31LeuVAR_000103rs149353983
3CFTRp.Ser42PheVAR_000104rs143456784
4CFTRp.Asp44GlyVAR_000105rs1800074
5CFTRp.Trp57GlyVAR_000108rs397508272
6CFTRp.Pro67LeuVAR_000109rs368505753
7CFTRp.Arg74TrpVAR_000110rs115545701
8CFTRp.Gly85GluVAR_000112rs75961395
9CFTRp.Phe87LeuVAR_000113rs397508403
10CFTRp.Gly91ArgVAR_000114rs121908750
11CFTRp.Glu92LysVAR_000115rs121908751
12CFTRp.Gln98ArgVAR_000116rs397508464
13CFTRp.Ile105SerVAR_000117
14CFTRp.Tyr109CysVAR_000118rs121909031
15CFTRp.Asp110HisVAR_000119rs113993958
16CFTRp.Arg117CysVAR_000121rs77834169
17CFTRp.Arg117HisVAR_000122rs78655421
18CFTRp.Arg117LeuVAR_000123rs78655421
19CFTRp.Arg117ProVAR_000124rs78655421
20CFTRp.Ala120ThrVAR_000125rs201958172
21CFTRp.His139ArgVAR_000126rs76371115
22CFTRp.Ala141AspVAR_000127rs397508700
23CFTRp.Ile148ThrVAR_000128rs35516286
24CFTRp.Gly178ArgVAR_000130rs80282562
25CFTRp.Glu193LysVAR_000132rs397508759
26CFTRp.His199GlnVAR_000133rs397508765
27CFTRp.His199TyrVAR_000134rs121908802
28CFTRp.Pro205SerVAR_000135rs121908803
29CFTRp.Leu206TrpVAR_000136rs121908752
30CFTRp.Cys225ArgVAR_000137rs397508780
31CFTRp.Asn287TyrVAR_000140rs397508804
32CFTRp.Arg297GlnVAR_000141rs143486492
33CFTRp.Tyr301CysVAR_000142rs150691494
34CFTRp.Ser307AsnVAR_000143rs397508817
35CFTRp.Phe311LeuVAR_000144rs121909016
36CFTRp.Gly314GluVAR_000146rs75763344
37CFTRp.Gly314ArgVAR_000147rs397508819
38CFTRp.Arg334TrpVAR_000148rs121909011
39CFTRp.Ile336LysVAR_000150rs397508139
40CFTRp.Thr338IleVAR_000151rs77409459
41CFTRp.Leu346ProVAR_000152rs397508146
42CFTRp.Arg347HisVAR_000153rs77932196
43CFTRp.Arg347LeuVAR_000154rs77932196
44CFTRp.Arg347ProVAR_000155rs77932196
45CFTRp.Arg352GlnVAR_000156rs121908753
46CFTRp.Gln359LysVAR_000157rs76879328
47CFTRp.Ala455GluVAR_000160rs74551128
48CFTRp.Val456PheVAR_000161rs397508195
49CFTRp.Gly458ValVAR_000162rs121909009
50CFTRp.Gly480CysVAR_000165rs79282516
51CFTRp.Ser492PheVAR_000166rs121909017
52CFTRp.Glu504GlnVAR_000167rs397508223
53CFTRp.Val520PheVAR_000174rs77646904
54CFTRp.Ser549AsnVAR_000176rs121908755
55CFTRp.Ser549IleVAR_000177rs121908755
56CFTRp.Ser549ArgVAR_000178rs121909005
57CFTRp.Gly551AspVAR_000179rs75527207
58CFTRp.Gly551SerVAR_000180rs121909013
59CFTRp.Arg553GlnVAR_000181rs121909044
60CFTRp.Leu558SerVAR_000182rs193922504
61CFTRp.Ala559ThrVAR_000183rs75549581
62CFTRp.Arg560LysVAR_000184rs80055610
63CFTRp.Arg560SerVAR_000185rs397508267
64CFTRp.Arg560ThrVAR_000186rs80055610
65CFTRp.Val562LeuVAR_000188rs1800097
66CFTRp.Tyr563AsnVAR_000189rs121909006
67CFTRp.Tyr569CysVAR_000190rs397508277
68CFTRp.Tyr569AspVAR_000191rs397508276
69CFTRp.Tyr569HisVAR_000192rs397508276
70CFTRp.Leu571SerVAR_000193rs397508280
71CFTRp.Asp572AsnVAR_000194rs397508282
72CFTRp.Pro574HisVAR_000195rs121908758
73CFTRp.Asp579GlyVAR_000197rs397508288
74CFTRp.Ile601PheVAR_000198rs397508306
75CFTRp.Leu610SerVAR_000199rs397508311
76CFTRp.Ala613ThrVAR_000200rs201978662
77CFTRp.Asp614GlyVAR_000201rs201124247
78CFTRp.Ile618ThrVAR_000202rs139468767
79CFTRp.Leu619SerVAR_000203rs397508313
80CFTRp.His620ProVAR_000204rs397508314
81CFTRp.His620GlnVAR_000205rs397508315
82CFTRp.Gly628ArgVAR_000207rs397508316
83CFTRp.Leu633ProVAR_000208rs397508318
84CFTRp.Asp648ValVAR_000209rs121909033
85CFTRp.Asp651AsnVAR_000210rs780526529
86CFTRp.Thr665SerVAR_000211
87CFTRp.Val754MetVAR_000214rs150157202
88CFTRp.Glu822LysVAR_000219rs397508378
89CFTRp.Cys866TyrVAR_000221rs193922506
90CFTRp.Tyr913CysVAR_000223rs121909008
91CFTRp.Tyr917CysVAR_000224rs397508428
92CFTRp.His949TyrVAR_000225rs121909035
93CFTRp.Met952IleVAR_000226rs151048781
94CFTRp.Leu997PheVAR_000227rs1800111
95CFTRp.Ile1005ArgVAR_000228rs397508479
96CFTRp.Ala1006GluVAR_000229rs397508480
97CFTRp.Pro1013LeuVAR_000230rs193922516
98CFTRp.Met1028IleVAR_000231rs200553511
99CFTRp.Phe1052ValVAR_000232rs150212784
100CFTRp.Gly1061ArgVAR_000233rs142394380
101CFTRp.Leu1065ProVAR_000234rs121909036
102CFTRp.Leu1065ArgVAR_000235rs121909036
103CFTRp.Arg1066CysVAR_000236rs78194216
104CFTRp.Arg1066HisVAR_000237rs121909019
105CFTRp.Arg1066LeuVAR_000238rs121909019
106CFTRp.Ala1067ThrVAR_000239rs121909020
107CFTRp.Arg1070GlnVAR_000241rs78769542
108CFTRp.Arg1070ProVAR_000242rs78769542
109CFTRp.Gln1071ProVAR_000243rs121909037
110CFTRp.Pro1072LeuVAR_000244
111CFTRp.Leu1077ProVAR_000245rs139304906
112CFTRp.His1085ArgVAR_000246rs79635528
113CFTRp.Trp1098ArgVAR_000247rs397508531
114CFTRp.Met1101LysVAR_000248rs36210737
115CFTRp.Met1137ValVAR_000249rs397508553
116CFTRp.Asp1152HisVAR_000251rs75541969
117CFTRp.Ile1234ValVAR_000254rs75389940
118CFTRp.Ser1235ArgVAR_000255rs34911792
119CFTRp.Gly1244GluVAR_000256rs267606723
120CFTRp.Gly1249GluVAR_000257rs121909040
121CFTRp.Ser1251AsnVAR_000258rs74503330
122CFTRp.Ser1255ProVAR_000259rs121909041
123CFTRp.Asp1270AsnVAR_000260rs11971167
124CFTRp.Trp1282ArgVAR_000261rs397508616
125CFTRp.Arg1283MetVAR_000262rs77902683
126CFTRp.Phe1286SerVAR_000263rs121909028
127CFTRp.Gln1291HisVAR_000264rs121909015
128CFTRp.Gln1291ArgVAR_000265rs397508621
129CFTRp.Asn1303HisVAR_000266rs121909042
130CFTRp.Asn1303LysVAR_000267rs80034486
131CFTRp.Gly1349AspVAR_000268rs193922525
132CFTRp.Val1397GluVAR_000270rs397508691
133CFTRp.Met1101ArgVAR_011565rs36210737

Clinvar genetic disease variations for Cystic Fibrosis:

5 (show all 393)
id Gene Variation Type Significance SNP ID Assembly Location
1TGFB1NM_ 000660.6(TGFB1): c.29C> T (p.Pro10Leu)SNVrisk factorrs1800470GRCh37Chr 19, 41858921: 41858921
2CFTRNM_ 000492.3(CFTR): c.3963+1G> ASNVPathogenicrs672601314GRCh38Chr 7, 117652932: 117652932
3CFTRNM_ 000492.3(CFTR): c.2700T> A (p.Asn900Lys)SNVPathogenicrs672601315GRCh38Chr 7, 117603574: 117603574
4CFTRNM_ 000492.3(CFTR): c.1117G> A (p.Asp373Asn)SNVPathogenicrs556880586GRCh38Chr 7, 117542016: 117542016
5CFTRNM_ 000492.3(CFTR): c.2443G> T (p.Glu815Ter)SNVPathogenicrs672601316GRCh38Chr 7, 117592610: 117592610
6CFTRNM_ 000492.3(CFTR): c.830G> A (p.Trp277Ter)SNVPathogenicrs672601317GRCh38Chr 7, 117536634: 117536634
7CFTRNM_ 000492.3(CFTR): c.3368-2A> GSNVPathogenicrs755416052GRCh38Chr 7, 117614611: 117614611
8CFTRNM_ 000492.3(CFTR): c.1327_ 1330dupGATA (p.Ile444Argfs)duplicationPathogenicrs397508189GRCh37Chr 7, 117188812: 117188815
9CFTRNM_ 000492.3(CFTR): c.850dupA (p.Met284Asnfs)duplicationPathogenic/ Likely pathogenicrs786204693GRCh37Chr 7, 117176708: 117176708
10CFTRNM_ 000492.3(CFTR): c.848_ 860delAAATGATTGAAAAinsTG (p.Lys283Metfs)indelPathogenicrs796065332GRCh37Chr 7, 117176706: 117176718
11CFTRNM_ 000492.3(CFTR): c.2462_ 2463delGT (p.Ser821Argfs)deletionPathogenicrs797045156GRCh37Chr 7, 117232683: 117232684
12CFTRNM_ 000492.3(CFTR): c.2658-1G> CSNVPathogenicrs397508416GRCh37Chr 7, 117243585: 117243585
13CFTRNM_ 000492.3(CFTR): c.2423_ 2424dupAT (p.Ser809Ilefs)duplicationPathogenicrs387906359GRCh37Chr 7, 117232644: 117232645
14CFTRNM_ 000492.3(CFTR): c.350G> A (p.Arg117His)SNV, HaplotypePathogenicrs78655421GRCh37Chr 7, 117171029: 117171029
15CFTRNM_ 000492.3(CFTR): c.(2988+1_ 2989-1)_ (3468+1_ 3469-1)deldeletionPathogenic
16CFTRNM_ 000492.3(CFTR): c.(53+1_ 54-1)_ (164+1_ 165-1)deldeletionPathogenic
17CFTRNM_ 000492.3(CFTR): c.(3963+1_ 3964-1)_ (*1_ ?)deldeletionPathogenic
18CFTRNM_ 000492.3(CFTR): c.(2619+1_ 2620-1)_ (3367+1_ 3368-1)deldeletionPathogenic
19CFTRNM_ 000492.3(CFTR): c.(2988+1_ 2989-1)_ (3367+1_ 3368-1)deldeletionPathogenic
20CFTRNM_ 000492.3(CFTR): c.(743+1_ 744-1)_ (1584+1_ 1585-1)dupduplicationPathogenic
21CFTRNM_ 000492.3(CFTR): c.3899dupT (p.Arg1301Terfs)duplicationPathogenicrs797045158GRCh37Chr 7, 117292921: 117292921
22CFTRNM_ 000492.3(CFTR): c.(2908+1_ 2909-1)_ (3367+1_ 3368-1)deldeletionPathogenic
23CFTRNM_ 000492.3(CFTR): c.3747delG (p.Lys1250Argfs)deletionPathogenicrs797045159GRCh37Chr 7, 117282521: 117282521
24CFTRNM_ 000492.3(CFTR): c.3294G> A (p.Trp1098Ter)SNVPathogenicrs397508533GRCh37Chr 7, 117251789: 117251789
25CFTRNM_ 000492.3(CFTR): c.(3468+1_ 3469-1)_ (3717+1_ 3718-1)deldeletionPathogenic
26CFTRNM_ 000492.3(CFTR): c.1117-1G> ASNVPathogenicrs797045160GRCh37Chr 7, 117182069: 117182069
27CFTRNM_ 000492.3(CFTR): c.(?_ 1)_ (53+1_ 54-1)deldeletionPathogenic
28CFTRNM_ 000492.3(CFTR): c.1365_ 1366delGG (p.Val456Cysfs)deletionPathogenicrs797045161GRCh37Chr 7, 117188850: 117188851
29CFTRNM_ 000492.3(CFTR): c.(273+1_ 274-1)_ (1116+1_ 1117-1)deldeletionPathogenic
30CFTRNM_ 000492.3(CFTR): c.(273+1_ 274-1)_ (1116+1_ 1117-1)del(1584+1_ 1585-1)_ (3468+1_ 3469-1)deldeletionPathogenic
31CFTRNM_ 000492.3(CFTR): c.(1584+1_ 1585-1)_ (1679+1_ 1680-1)deldeletionPathogenic
32CFTRNM_ 000492.3(CFTR): c.(53+1_ 54-1)_ (489+1_ 490-1)deldeletionPathogenic
33CFTRNM_ 000492.3(CFTR): c.2053dupC (p.Gln685Profs)duplicationPathogenicrs797045162GRCh37Chr 7, 117232274: 117232274
34CFTRNM_ 000492.3(CFTR): c.(1766+1_ 1767-1)_ (2619+1_ 2620-1)deldeletionPathogenic
35CFTRNM_ 000492.3(CFTR): c.744-?_ 1584+?dupduplicationPathogenic
36CFTRNM_ 000492.3(CFTR): c.1234_ 1238delGCAAA (p.Ala412Thrfs)deletionPathogenicrs3034796GRCh37Chr 7, 117188719: 117188723
37CFTRNM_ 000492.3(CFTR): c.3999delG (p.Lys1334Serfs)deletionPathogenicrs886042527GRCh37Chr 7, 117304777: 117304777
38CFTRNM_ 000492.3(CFTR): c.1679+1G> ASNVPathogenicrs397508263GRCh37Chr 7, 117227888: 117227888
39CFTRNM_ 000492.3(CFTR): c.114C> G (p.Tyr38Ter)SNVLikely pathogenicrs193922498GRCh37Chr 7, 117144367: 117144367
40CFTRNM_ 000492.3(CFTR): c.1367T> C (p.Val456Ala)SNVLikely pathogenicrs193922500GRCh37Chr 7, 117188852: 117188852
41CFTRNM_ 000492.3(CFTR): c.1397C> G (p.Ser466Ter)SNVPathogenicrs121908805GRCh37Chr 7, 117199522: 117199522
42CFTRNM_ 000492.3(CFTR): c.1400T> C (p.Leu467Pro)SNVPathogenicrs139573311GRCh37Chr 7, 117199525: 117199525
43CFTRNM_ 000492.3(CFTR): c.1585-8G> ASNVPathogenicrs193922503GRCh37Chr 7, 117227785: 117227785
44CFTRNM_ 000492.3(CFTR): c.1673T> C (p.Leu558Ser)SNVLikely pathogenicrs193922504GRCh37Chr 7, 117227881: 117227881
45CFTRNM_ 000492.3(CFTR): c.1692delA (p.Asp565Metfs)deletionPathogenicrs193922505GRCh37Chr 7, 117230419: 117230419
46CFTRNM_ 000492.3(CFTR): c.1865G> A (p.Gly622Asp)SNVPathogenicrs121908759GRCh37Chr 7, 117232086: 117232086
47CFTRNM_ 000492.3(CFTR): c.1911delG (p.Gln637Hisfs)deletionPathogenicrs121908778GRCh37Chr 7, 117232132: 117232132
48CFTRNM_ 000492.3(CFTR): c.2012delT (p.Leu671Terfs)deletionPathogenicrs121908812GRCh37Chr 7, 117232233: 117232233
49CFTRNM_ 000492.3(CFTR): c.2051_ 2052delAAinsG (p.Lys684Serfs)indelPathogenicrs121908799GRCh37Chr 7, 117232272: 117232273
50CFTRNM_ 000492.3(CFTR): c.2052dupA (p.Gln685Thrfs)duplicationPathogenicrs121908786GRCh37Chr 7, 117232273: 117232273
51CFTRNM_ 000492.3(CFTR): c.273+3A> CSNVPathogenicrs74467662GRCh37Chr 7, 117149199: 117149199
52CFTRNM_ 000492.3(CFTR): c.2768C> A (p.Ala923Asp)SNVLikely pathogenicrs193922509GRCh37Chr 7, 117243696: 117243696
53CFTRNM_ 000492.3(CFTR): c.2810dupT (p.Val938Glyfs)duplicationPathogenicrs193922510GRCh37Chr 7, 117243738: 117243738
54CFTRNM_ 000492.3(CFTR): c.2813T> G (p.Val938Gly)SNVPathogenicrs193922511GRCh37Chr 7, 117243741: 117243741
55CFTRNM_ 000492.3(CFTR): c.2909G> A (p.Gly970Asp)SNVLikely pathogenicrs386134230GRCh37Chr 7, 117246728: 117246728
56CFTRNM_ 000492.3(CFTR): c.2932A> T (p.Lys978Ter)SNVLikely pathogenicrs193922514GRCh37Chr 7, 117246751: 117246751
57CFTRNM_ 000492.3(CFTR): c.2988G> A (p.Gln996=)SNVPathogenicrs121908797GRCh37Chr 7, 117246807: 117246807
58CFTRNM_ 000492.3(CFTR): c.2989-2A> TSNVLikely pathogenicrs193922515GRCh37Chr 7, 117250571: 117250571
59CFTRNM_ 000492.3(CFTR): c.3038C> A (p.Pro1013His)SNVLikely pathogenicrs193922516GRCh37Chr 7, 117250622: 117250622
60CFTRNM_ 000492.3(CFTR): c.3095A> G (p.Tyr1032Cys)SNVPathogenicrs144055758GRCh37Chr 7, 117250679: 117250679
61CFTRNM_ 000492.3(CFTR): c.3140-26A> GSNVPathogenicrs76151804GRCh37Chr 7, 117251609: 117251609
62CFTRNM_ 000492.3(CFTR): c.3209G> A (p.Arg1070Gln)SNVPathogenic/ Likely pathogenicrs78769542GRCh37Chr 7, 117251704: 117251704
63CFTRNM_ 000492.3(CFTR): c.3454G> C (p.Asp1152His)SNVPathogenicrs75541969GRCh37Chr 7, 117254753: 117254753
64CFTRNM_ 000492.3(CFTR): c.3528delC (p.Lys1177Serfs)deletionPathogenicrs121908747GRCh37Chr 7, 117267635: 117267635
65CFTRNM_ 000492.3(CFTR): c.355A> G (p.Ile119Val)SNVLikely pathogenicrs193922518GRCh37Chr 7, 117171034: 117171034
66CFTRNM_ 000492.3(CFTR): c.3691delT (p.Ser1231Profs)deletionPathogenicrs121908783GRCh37Chr 7, 117267798: 117267798
67CFTRNM_ 000492.3(CFTR): c.370G> C (p.Gly124Arg)SNVLikely pathogenicrs193922519GRCh37Chr 7, 117171049: 117171049
68CFTRNM_ 000492.3(CFTR): c.3717+5G> ASNVLikely pathogenicrs193922520GRCh37Chr 7, 117267829: 117267829
69CFTRNM_ 000492.3(CFTR): c.380_ 382dupTAT (p.Leu127_ Cys128insLeu)duplicationLikely pathogenicrs193922521GRCh37Chr 7, 117171059: 117171061
70CFTRNM_ 000492.3(CFTR): c.3957_ 3958insAGGG (p.Asp1320Argfs)insertionLikely pathogenicrs193922523GRCh37Chr 7, 117292979: 117292980
71CFTRNM_ 000492.3(CFTR): c.3997G> T (p.Gly1333Trp)SNVLikely pathogenicrs193922524GRCh37Chr 7, 117304775: 117304775
72CFTRNM_ 000492.3(CFTR): c.4046G> A (p.Gly1349Asp)SNVPathogenic/ Likely pathogenic, drug responsers193922525GRCh37Chr 7, 117304824: 117304824
73CFTRNM_ 000492.3(CFTR): c.4242+2T> CSNVLikely pathogenicrs193922526GRCh37Chr 7, 117305620: 117305620
74CFTRNM_ 000492.3(CFTR): c.4280T> C (p.Ile1427Thr)SNVLikely pathogenicrs193922528GRCh37Chr 7, 117306999: 117306999
75CFTRNM_ 000492.3(CFTR): c.592G> A (p.Ala198Thr)SNVLikely pathogenicrs193922529GRCh37Chr 7, 117175314: 117175314
76CFTRNM_ 000492.3(CFTR): c.825C> G (p.Tyr275Ter)SNVPathogenicrs193922532GRCh37Chr 7, 117176683: 117176683
77CFTRNM_ 000492.3(CFTR): c.846A> T (p.Glu282Asp)SNVLikely pathogenicrs142864834GRCh37Chr 7, 117176704: 117176704
78CFTRNM_ 000492.3(CFTR): c.997C> T (p.Leu333Phe)SNVLikely pathogenicrs193922533GRCh37Chr 7, 117180281: 117180281
79CFTRNM_ 000492.3(CFTR): c.3536_ 3539delCCAA (p.Thr1179Asnfs)deletionLikely pathogenicrs121908782GRCh37Chr 7, 117267643: 117267646
80CFTRNM_ 000492.3(CFTR): c.2490+2T> CSNVLikely pathogenicrs1057516216GRCh38Chr 7, 117592659: 117592659
81CFTRNM_ 000492.3(CFTR): c.56G> A (p.Trp19Ter)SNVLikely pathogenicrs1057516232GRCh37Chr 7, 117144309: 117144309
82CFTRNM_ 000492.3(CFTR): c.2429delG (p.Arg810Lysfs)deletionLikely pathogenicrs1057516236GRCh37Chr 7, 117232650: 117232650
83CFTRNM_ 000492.3(CFTR): c.3963+1G> CSNVLikely pathogenicrs672601314GRCh38Chr 7, 117652932: 117652932
84CFTRNM_ 000492.3(CFTR): c.888_ 889dupTC (p.Arg297Leufs)duplicationLikely pathogenicrs1057516387GRCh37Chr 7, 117180172: 117180173
85CFTRNM_ 000492.3(CFTR): c.4300_ 4301dupAG (p.Ser1435Glyfs)duplicationPathogenicrs397508709GRCh37Chr 7, 117307019: 117307020
86CFTRNM_ 000492.3(CFTR): c.2993delT (p.Leu998Tyrfs)deletionLikely pathogenicrs1057516415GRCh38Chr 7, 117610523: 117610523
87CFTRNM_ 000492.3(CFTR): c.3988_ 3989delCA (p.Gln1330Valfs)deletionLikely pathogenicrs1057516457GRCh37Chr 7, 117304766: 117304767
88CFTRNM_ 000492.3(CFTR): c.3944_ 3951delTATGGAAA (p.Ile1315Serfs)deletionLikely pathogenicrs1057516527GRCh38Chr 7, 117652912: 117652919
89CFTRNM_ 000492.3(CFTR): c.3533C> A (p.Ser1178Ter)SNVLikely pathogenicrs1057516609GRCh38Chr 7, 117627586: 117627586
90CFTRNM_ 000492.3(CFTR): c.865A> T (p.Arg289Ter)SNVLikely pathogenicrs1057516619GRCh38Chr 7, 117536669: 117536669
91CFTRNM_ 000492.3(CFTR): c.744-2A> GSNVLikely pathogenicrs1057516646GRCh37Chr 7, 117176600: 117176600
92CFTRNM_ 000492.3(CFTR): c.3139+1delGdeletionLikely pathogenicrs1057516794GRCh38Chr 7, 117610670: 117610670
93CFTRNM_ 000492.3(CFTR): c.1209+1G> TSNVLikely pathogenicrs397508176GRCh38Chr 7, 117542109: 117542109
94CFTRNM_ 000492.3(CFTR): c.3495delG (p.Lys1165Asnfs)deletionLikely pathogenicrs1057516970GRCh37Chr 7, 117267602: 117267602
95CFTRNM_ 000492.3(CFTR): c.2854delA (p.Met952Cysfs)deletionLikely pathogenicrs1057517032GRCh38Chr 7, 117603728: 117603728
96CFTRNM_ 000492.3(CFTR): c.2554dupT (p.Tyr852Leufs)duplicationLikely pathogenicrs1057517068GRCh37Chr 7, 117235047: 117235047
97CFTRNM_ 000492.3(CFTR): c.4143C> G (p.Tyr1381Ter)SNVLikely pathogenicrs397508683GRCh38Chr 7, 117665465: 117665465
98CFTRNM_ 000492.3(CFTR): c.3368-2A> TSNVLikely pathogenicrs755416052GRCh38Chr 7, 117614611: 117614611
99CFTRNM_ 000492.3(CFTR): c.4272C> G (p.Tyr1424Ter)SNVLikely pathogenicrs1800135GRCh38Chr 7, 117666937: 117666937
100CFTRNM_ 000492.3(CFTR): c.2483dupA (p.Asp828Glufs)duplicationLikely pathogenicrs1057517276GRCh37Chr 7, 117232704: 117232704
101CFTRNM_ 000492.3(CFTR): c.739_ 742dupTACA (p.Arg248Ilefs)duplicationLikely pathogenicrs1057517342GRCh38Chr 7, 117535407: 117535410
102CFTRNM_ 000492.3(CFTR): c.3851_ 3852dupAA (p.Ala1285Lysfs)duplicationLikely pathogenicrs1057517404GRCh38Chr 7, 117642571: 117642572
103CFTRNP_ 000483.3(CFTR): p.Tyr1092Terprotein onlyPathogenic
104CFTRNP_ 000483.3: p.Ser549Argprotein onlyPathogenic
105CFTRNM_ 000492.3(CFTR): c.3067_ 3072delATAGTG (p.Ile1023_ Val1024del)deletionPathogenicrs121908767GRCh37Chr 7, 117250651: 117250656
106CFTRNM_ 000492.3(CFTR): c.2052delA (p.Lys684Asnfs)deletionPathogenicrs121908746GRCh37Chr 7, 117232273: 117232273
107CFTRNM_ 000492.3(CFTR): c.579+1G> TSNVPathogenicrs77188391GRCh37Chr 7, 117174420: 117174420
108CFTRNM_ 000492.3(CFTR): c.2657+5G> ASNVPathogenicrs80224560GRCh37Chr 7, 117242922: 117242922
109CFTRNM_ 000492.3(CFTR): c.3773dupT (p.Leu1258Phefs)duplicationPathogenicrs121908789GRCh37Chr 7, 117282547: 117282547
110CFTRNM_ 000492.3(CFTR): c.178G> T (p.Glu60Ter)SNVPathogenicrs77284892GRCh37Chr 7, 117149101: 117149101
111CFTRNM_ 000492.3(CFTR): c.1923_ 1931delCTCAAAACTinsA (p.Ser641Argfs)indelPathogenicrs121908779GRCh37Chr 7, 117232144: 117232152
112CFTRNM_ 000492.3(CFTR): c.489+1G> TSNVPathogenicrs78756941GRCh37Chr 7, 117171169: 117171169
113CFTRNM_ 000492.3(CFTR): c.366T> A (p.Tyr122Ter)SNVPathogenicrs79660178GRCh37Chr 7, 117171045: 117171045
114CFTRNM_ 000492.3(CFTR): c.3302T> A (p.Met1101Lys)SNVPathogenicrs36210737GRCh37Chr 7, 117251797: 117251797
115CFTRNM_ 000492.3(CFTR): c.3276C> G (p.Tyr1092Ter)SNVPathogenicrs121908761GRCh37Chr 7, 117251771: 117251771
116CFTRNM_ 000492.3(CFTR): c.2908+1G> ASNVLikely pathogenicrs1060503164GRCh38Chr 7, 117603783: 117603783
117CFTRNC_ 000007.14: g.(?_ 117504253)_ (117509142_ ?)deldeletionPathogenicGRCh37Chr 7, 117144307: 117149196
118CFTRNM_ 000492.3(CFTR): c.223C> T (p.Arg75Ter)SNVPathogenicrs121908749GRCh37Chr 7, 117149146: 117149146
119CFTRNM_ 000492.3(CFTR): c.3587C> G (p.Ser1196Ter)SNVPathogenicrs121908763GRCh37Chr 7, 117267694: 117267694
120CFTRNM_ 000492.3(CFTR): c.274-1G> ASNVPathogenicrs121908792GRCh37Chr 7, 117170952: 117170952
121CFTRNM_ 000492.3(CFTR): c.1680-1G> ASNVPathogenicrs121908794GRCh37Chr 7, 117230406: 117230406
122CFTRNM_ 000492.3(CFTR): c.313delA (p.Ile105Serfs)deletionPathogenicrs121908801GRCh37Chr 7, 117170992: 117170992
123CFTRNM_ 000492.3(CFTR): c.1766+5G> TSNVPathogenicrs121908796GRCh37Chr 7, 117230498: 117230498
124CFTRNM_ 000492.3(CFTR): c.349C> T (p.Arg117Cys)SNVPathogenicrs77834169GRCh37Chr 7, 117171028: 117171028
125CFTRNM_ 000492.3(CFTR): c.532G> A (p.Gly178Arg)SNVPathogenic, drug responsers80282562GRCh37Chr 7, 117174372: 117174372
126CFTRNM_ 000492.3(CFTR): c.803delA (p.Asn268Ilefs)deletionPathogenicrs121908772GRCh37Chr 7, 117176661: 117176661
127CFTRNM_ 000492.3(CFTR): c.935_ 937delTCT (p.Phe312del)deletionPathogenicrs121908768GRCh37Chr 7, 117180219: 117180221
128CFTRNM_ 000492.3(CFTR): c.988G> T (p.Gly330Ter)SNVPathogenicrs79031340GRCh37Chr 7, 117180272: 117180272
129CFTRNM_ 000492.3(CFTR): c.2989-977_ 3367+248deldeletionPathogenicGRCh37Chr 7, 117249596: 117252110
130CFTRNM_ 000492.3(CFTR): c.-9_ 14del23deletionPathogenicrs397508136GRCh37Chr 7, 117120140: 117120162
131CFTRNM_ 000492.3(CFTR): c.1006_ 1007insG (p.Ile336Serfs)insertionPathogenicrs397508138GRCh37Chr 7, 117180290: 117180291
132CFTRNM_ 000492.3(CFTR): c.1007T> A (p.Ile336Lys)SNVPathogenicrs397508139GRCh37Chr 7, 117180291: 117180291
133CFTRNM_ 000492.3(CFTR): c.1021T> C (p.Ser341Pro)SNVPathogenicrs397508144GRCh37Chr 7, 117180305: 117180305
134CFTRNM_ 000492.3(CFTR): c.1029delC (p.Cys343Terfs)deletionPathogenicrs121908774GRCh37Chr 7, 117180313: 117180313
135CFTRNM_ 000492.3(CFTR): c.1116+1G> ASNVPathogenicrs397508158GRCh37Chr 7, 117180401: 117180401
136CFTRNM_ 000492.3(CFTR): c.1128dupA (p.Gln378Alafs)duplicationPathogenicrs397508163GRCh37Chr 7, 117182081: 117182081
137CFTRNM_ 000492.3(CFTR): c.1152_ 1153dupAT (p.Asn386Ilefs)duplicationPathogenicrs121908785GRCh37Chr 7, 117182105: 117182106
138CFTRNM_ 000492.3(CFTR): c.115C> T (p.Gln39Ter)SNVPathogenicrs397508168GRCh37Chr 7, 117144368: 117144368
139CFTRNM_ 000492.3(CFTR): c.11C> A (p.Ser4Ter)SNVPathogenicrs397508173GRCh37Chr 7, 117120159: 117120159
140CFTRNM_ 000492.3(CFTR): c.1202G> A (p.Trp401Ter)SNVPathogenicrs397508174GRCh37Chr 7, 117182155: 117182155
141CFTRNM_ 000492.3(CFTR): c.1203G> A (p.Trp401Ter)SNVPathogenicrs397508175GRCh38Chr 7, 117542102: 117542102
142CFTRNM_ 000492.3(CFTR): c.1209+1G> ASNVPathogenicrs397508176GRCh37Chr 7, 117182163: 117182163
143CFTRNM_ 000492.3(CFTR): c.1240C> T (p.Gln414Ter)SNVPathogenicrs397508183GRCh38Chr 7, 117548671: 117548671
144CFTRNM_ 000492.3(CFTR): c.1340delA (p.Lys447Argfs)deletionPathogenicrs397508192GRCh37Chr 7, 117188825: 117188825
145CFTRNM_ 000492.3(CFTR): c.1373delG (p.Gly458Aspfs)deletionLikely pathogenicrs397508196GRCh37Chr 7, 117188858: 117188858
146CFTRNM_ 000492.3(CFTR): c.137C> A (p.Ala46Asp)SNVPathogenicrs151020603GRCh37Chr 7, 117144390: 117144390
147CFTRNM_ 000492.3(CFTR): c.1393-1G> ASNVPathogenicrs397508200GRCh37Chr 7, 117199517: 117199517
148CFTRNM_ 000492.3(CFTR): c.1393-2A> GSNVPathogenicrs397508201GRCh37Chr 7, 117199516: 117199516
149CFTRNM_ 000492.3(CFTR): c.1397C> A (p.Ser466Ter)SNVPathogenicrs121908805GRCh37Chr 7, 117199522: 117199522
150CFTRNM_ 000492.3(CFTR): c.1418delG (p.Gly473Glufs)deletionPathogenicrs397508205GRCh37Chr 7, 117199543: 117199543
151CFTRNM_ 000492.3(CFTR): c.1466C> A (p.Ser489Ter)SNVPathogenicrs397508211GRCh37Chr 7, 117199591: 117199591
152CFTRNM_ 000492.3(CFTR): c.148T> C (p.Ser50Pro)SNVLikely pathogenicrs397508217GRCh37Chr 7, 117144401: 117144401
153CFTRNM_ 000492.3(CFTR): c.1518C> G (p.Ile506Met)SNVPathogenicrs1800092GRCh37Chr 7, 117199643: 117199643
154CFTRNM_ 000492.3(CFTR): c.1573C> T (p.Gln525Ter)SNVPathogenicrs397508227GRCh37Chr 7, 117199698: 117199698
155CFTRNM_ 000492.3(CFTR): c.164+1G> ASNVPathogenicrs397508243GRCh37Chr 7, 117144418: 117144418
156CFTRNM_ 000492.3(CFTR): c.1648G> T (p.Gly550Ter)SNVPathogenicrs397508247GRCh37Chr 7, 117227856: 117227856
157CFTRNM_ 000492.3(CFTR): c.165-1G> ASNVPathogenicrs397508249GRCh37Chr 7, 117149087: 117149087
158CFTRNM_ 000492.3(CFTR): c.165-3C> TSNVLikely pathogenicrs200337193GRCh37Chr 7, 117149085: 117149085
159CFTRNM_ 000492.3(CFTR): c.1650delA (p.Gly551Valfs)deletionPathogenicrs397508251GRCh37Chr 7, 117227858: 117227858
160CFTRNM_ 000492.3(CFTR): c.166G> A (p.Glu56Lys)SNVPathogenicrs397508256GRCh37Chr 7, 117149089: 117149089
161CFTRNM_ 000492.3(CFTR): c.1679+1643G> TSNVLikely pathogenicrs397508261GRCh37Chr 7, 117229530: 117229530
162CFTRNM_ 000492.3(CFTR): c.1679+1G> CSNVPathogenicrs397508263GRCh37Chr 7, 117227888: 117227888
163CFTRNM_ 000492.3(CFTR): c.1680-886A> GSNVPathogenicrs397508266GRCh37Chr 7, 117229521: 117229521
164CFTRNM_ 000492.3(CFTR): c.1703T> A (p.Leu568Ter)SNVLikely pathogenicrs397508273GRCh37Chr 7, 117230430: 117230430
165CFTRNM_ 000492.3(CFTR): c.1705T> G (p.Tyr569Asp)SNVPathogenicrs397508276GRCh37Chr 7, 117230432: 117230432
166CFTRNM_ 000492.3(CFTR): c.170G> A (p.Trp57Ter)SNVPathogenicrs397508279GRCh37Chr 7, 117149093: 117149093
167CFTRNM_ 000492.3(CFTR): c.175dupA (p.Arg59Lysfs)duplicationPathogenicrs397508294GRCh37Chr 7, 117149098: 117149098
168CFTRNM_ 000492.3(CFTR): c.1753G> T (p.Glu585Ter)SNVPathogenicrs397508296GRCh37Chr 7, 117230480: 117230480
169CFTRNM_ 000492.3(CFTR): c.1766+1G> CSNVPathogenicrs121908748GRCh37Chr 7, 117230494: 117230494
170CFTRNM_ 000492.3(CFTR): c.1766+1G> TSNVLikely pathogenicrs121908748GRCh37Chr 7, 117230494: 117230494
171CFTRNM_ 000492.3(CFTR): c.1766+3A> GSNVPathogenicrs397508298GRCh37Chr 7, 117230496: 117230496
172CFTRNM_ 000492.3(CFTR): c.1792_ 1798delAAAACTA (p.Lys598Glyfs)deletionPathogenicrs397508303GRCh37Chr 7, 117232013: 117232019
173CFTRNM_ 000492.3(CFTR): c.1820_ 1903del84 (p.Met607_ Gln634del)deletionPathogenic/ Likely pathogenicrs121908777GRCh37Chr 7, 117232041: 117232124
174CFTRNM_ 000492.3(CFTR): c.1853T> C (p.Ile618Thr)SNVPathogenicrs139468767GRCh37Chr 7, 117232074: 117232074
175CFTRNM_ 000492.3(CFTR): c.1973_ 1985delGAAATTCAATCCTinsAGAAA (p.Arg658Lysfs)indelPathogenicrs121908780GRCh37Chr 7, 117232194: 117232206
176CFTRNM_ 000492.3(CFTR): c.1986_ 1989delAACT (p.Thr663Argfs)deletionPathogenicrs397508325GRCh37Chr 7, 117232207: 117232210
177CFTRNM_ 000492.3(CFTR): c.1A> G (p.Met1Val)SNVPathogenicrs397508328GRCh37Chr 7, 117120149: 117120149
178CFTRNM_ 000492.3(CFTR): c.200C> T (p.Pro67Leu)SNVPathogenicrs368505753GRCh37Chr 7, 117149123: 117149123
179CFTRNM_ 000492.3(CFTR): c.2017G> T (p.Gly673Ter)SNVPathogenicrs397508331GRCh37Chr 7, 117232238: 117232238
180CFTRNM_ 000492.3(CFTR): c.2036G> A (p.Trp679Ter)SNVLikely pathogenicrs397508333GRCh37Chr 7, 117232257: 117232257
181CFTRNM_ 000492.3(CFTR): c.2053C> T (p.Gln685Ter)SNVPathogenicrs397508336GRCh37Chr 7, 117232274: 117232274
182CFTRNM_ 000492.3(CFTR): c.2125C> T (p.Arg709Ter)SNVPathogenicrs121908760GRCh37Chr 7, 117232346: 117232346
183CFTRNM_ 000492.3(CFTR): c.2195T> G (p.Leu732Ter)SNVPathogenicrs397508350GRCh37Chr 7, 117232416: 117232416
184CFTRNM_ 000492.3(CFTR): c.2215delG (p.Val739Tyrfs)deletionPathogenicrs397508353GRCh37Chr 7, 117232436: 117232436
185CFTRNM_ 000492.3(CFTR): c.2290C> T (p.Arg764Ter)SNVPathogenicrs121908810GRCh37Chr 7, 117232511: 117232511
186CFTRNM_ 000492.3(CFTR): c.233dupT (p.Trp79Leufs)duplicationPathogenicrs397508360GRCh37Chr 7, 117149156: 117149156
187CFTRNM_ 000492.3(CFTR): c.2353C> T (p.Arg785Ter)SNVPathogenicrs374946172GRCh37Chr 7, 117232574: 117232574
188CFTRNM_ 000492.3(CFTR): c.2374C> T (p.Arg792Ter)SNVPathogenicrs145449046GRCh37Chr 7, 117232595: 117232595
189CFTRNM_ 000492.3(CFTR): c.2464G> T (p.Glu822Ter)SNVPathogenicrs397508378GRCh37Chr 7, 117232685: 117232685
190CFTRNM_ 000492.3(CFTR): c.2491G> T (p.Glu831Ter)SNVPathogenicrs397508387GRCh37Chr 7, 117234984: 117234984
191CFTRNM_ 000492.3(CFTR): c.2537G> A (p.Trp846Ter)SNVPathogenicrs397508393GRCh37Chr 7, 117235030: 117235030
192CFTRNM_ 000492.3(CFTR): c.2547C> A (p.Tyr849Ter)SNVPathogenicrs397508394GRCh37Chr 7, 117235040: 117235040
193CFTRNM_ 000492.3(CFTR): c.2583delT (p.Phe861Leufs)deletionPathogenicrs397508399GRCh37Chr 7, 117235076: 117235076
194CFTRNM_ 000492.3(CFTR): c.2589_ 2599delAATTTGGTGCT (p.Ile864Serfs)deletionPathogenicrs397508400GRCh37Chr 7, 117235082: 117235092
195CFTRNM_ 000492.3(CFTR): c.2601dupA (p.Val868Serfs)duplicationPathogenicrs397508405GRCh37Chr 7, 117235094: 117235094
196CFTRNM_ 000492.3(CFTR): c.263T> G (p.Leu88Ter)SNVLikely pathogenicrs397508412GRCh37Chr 7, 117149186: 117149186
197CFTRNM_ 000492.3(CFTR): c.273+1G> ASNVPathogenicrs121908791GRCh37Chr 7, 117149197: 117149197
198CFTRNM_ 000492.3(CFTR): c.2735C> A (p.Ser912Ter)SNVPathogenicrs121909034GRCh37Chr 7, 117243663: 117243663
199CFTRNM_ 000492.3(CFTR): c.2739T> A (p.Tyr913Ter)SNVPathogenicrs149790377GRCh37Chr 7, 117243667: 117243667
200CFTRNM_ 000492.3(CFTR): c.2763_ 2764dupAG (p.Val922Glufs)duplicationPathogenicrs397508431GRCh37Chr 7, 117243691: 117243692
201CFTRNM_ 000492.3(CFTR): c.2780T> C (p.Leu927Pro)SNVPathogenicrs397508435GRCh37Chr 7, 117243708: 117243708
202CFTRNM_ 000492.3(CFTR): c.2825delT (p.Ile942Thrfs)deletionPathogenicrs397508441GRCh37Chr 7, 117243753: 117243753
203CFTRNM_ 000492.3(CFTR): c.2834C> T (p.Ser945Leu)SNVPathogenicrs397508442GRCh37Chr 7, 117243762: 117243762
204CFTRNM_ 000492.3(CFTR): c.2859_ 2890del32 (p.Leu953Phefs)deletionPathogenicrs397508445GRCh37Chr 7, 117243787: 117243818
205CFTRNM_ 000492.3(CFTR): c.2875delG (p.Ala959Hisfs)deletionPathogenicrs397508447GRCh37Chr 7, 117243803: 117243803
206CFTRNM_ 000492.3(CFTR): c.2896delA (p.Thr966Argfs)deletionPathogenicrs397508451GRCh37Chr 7, 117243824: 117243824
207CFTRNM_ 000492.3(CFTR): c.2908G> C (p.Gly970Arg)SNVPathogenicrs397508453GRCh37Chr 7, 117243836: 117243836
208CFTRNM_ 000492.3(CFTR): c.292C> T (p.Gln98Ter)SNVPathogenicrs397508461GRCh37Chr 7, 117170971: 117170971
209CFTRNM_ 000492.3(CFTR): c.2989-1G> ASNVPathogenicrs397508470GRCh37Chr 7, 117250572: 117250572
210CFTRNM_ 000492.3(CFTR): c.2989-2A> GSNVPathogenicrs193922515GRCh37Chr 7, 117250571: 117250571
211CFTRNM_ 000492.3(CFTR): c.2997_ 3000delAATT (p.Ile1000Terfs)deletionLikely pathogenicrs397508472GRCh37Chr 7, 117250581: 117250584
212CFTRNM_ 000492.3(CFTR): c.2T> C (p.Met1Thr)SNVLikely pathogenicrs397508476GRCh37Chr 7, 117120150: 117120150
213CFTRNM_ 000492.3(CFTR): c.3002_ 3003delTG (p.Val1001Aspfs)deletionPathogenicrs397508477GRCh37Chr 7, 117250586: 117250587
214CFTRNM_ 000492.3(CFTR): c.3022delG (p.Val1008Serfs)deletionLikely pathogenicrs397508482GRCh37Chr 7, 117250606: 117250606
215CFTRNM_ 000492.3(CFTR): c.3039delC (p.Tyr1014Thrfs)deletionPathogenicrs121908781GRCh37Chr 7, 117250623: 117250623
216CFTRNM_ 000492.3(CFTR): c.3103C> T (p.Gln1035Ter)SNVLikely pathogenicrs397508496GRCh37Chr 7, 117250687: 117250687
217CFTRNM_ 000492.3(CFTR): c.310delA (p.Arg104Glufs)deletionPathogenicrs397508499GRCh37Chr 7, 117170989: 117170989
218CFTRNM_ 000492.3(CFTR): c.3139_ 3139+1delGGdeletionLikely pathogenicrs397508505GRCh37Chr 7, 117250723: 117250724
219CFTRNM_ 000492.3(CFTR): c.3160C> G (p.His1054Asp)SNVPathogenicrs397508510GRCh37Chr 7, 117251655: 117251655
220CFTRNM_ 000492.3(CFTR): c.3181G> C (p.Gly1061Arg)SNVPathogenicrs142394380GRCh37Chr 7, 117251676: 117251676
221CFTRNM_ 000492.3(CFTR): c.3208C> T (p.Arg1070Trp)SNVPathogenicrs202179988GRCh37Chr 7, 117251703: 117251703
222CFTRNM_ 000492.3(CFTR): c.3222T> A (p.Phe1074Leu)SNVLikely pathogenicrs186045772GRCh37Chr 7, 117251717: 117251717
223CFTRNM_ 000492.3(CFTR): c.3230T> C (p.Leu1077Pro)SNVPathogenicrs139304906GRCh37Chr 7, 117251725: 117251725
224CFTRNM_ 000492.3(CFTR): c.325_ 327delTATinsG (p.Tyr109Glyfs)indelPathogenicrs121908798GRCh37Chr 7, 117171004: 117171006
225CFTRNM_ 000492.3(CFTR): c.3293G> A (p.Trp1098Ter)SNVPathogenicrs397508532GRCh37Chr 7, 117251788: 117251788
226CFTRNM_ 000492.3(CFTR): c.3304A> T (p.Arg1102Ter)SNVPathogenicrs397508536GRCh37Chr 7, 117251799: 117251799
227CFTRNM_ 000492.3(CFTR): c.3310G> T (p.Glu1104Ter)SNVPathogenicrs397508538GRCh37Chr 7, 117251805: 117251805
228CFTRNM_ 000492.3(CFTR): c.3605delA (p.Asp1202Alafs)deletionPathogenicrs397508587GRCh37Chr 7, 117267712: 117267712
229CFTRNM_ 000492.3(CFTR): c.3612G> A (p.Trp1204Ter)SNVPathogenicrs121908765GRCh37Chr 7, 117267719: 117267719
230CFTRNM_ 000492.3(CFTR): c.3718-3T> GSNVPathogenicrs397508596GRCh37Chr 7, 117282489: 117282489
231CFTRNM_ 000492.3(CFTR): c.3731G> A (p.Gly1244Glu)SNVPathogenic, drug responsers267606723GRCh37Chr 7, 117282505: 117282505
232CFTRNM_ 000492.3(CFTR): c.3761T> G (p.Leu1254Ter)SNVPathogenicrs397508604GRCh37Chr 7, 117282535: 117282535
233CFTRNM_ 000492.3(CFTR): c.3883_ 3886delATTT (p.Ile1295Phefs)deletionPathogenicrs387906373GRCh37Chr 7, 117292905: 117292908
234CFTRNM_ 000492.3(CFTR): c.3883delA (p.Ile1295Phefs)deletionPathogenicrs397508630GRCh37Chr 7, 117292905: 117292905
235CFTRNM_ 000492.3(CFTR): c.3889dupT (p.Ser1297Phefs)duplicationPathogenicrs121908808GRCh37Chr 7, 117292911: 117292911
236CFTRNM_ 000492.3(CFTR): c.3908delA (p.Asn1303Thrfs)deletionPathogenicrs397508637GRCh37Chr 7, 117292930: 117292930
237CFTRNM_ 000492.3(CFTR): c.3929G> A (p.Trp1310Ter)SNVLikely pathogenicrs397508645GRCh37Chr 7, 117292951: 117292951
238CFTRNM_ 000492.3(CFTR): c.4077_ 4080delTGTTinsAA (p.Val1360Thrfs)indelPathogenicrs397508668GRCh37Chr 7, 117304855: 117304858
239CFTRNM_ 000492.3(CFTR): c.4086dupT (p.Lys1363Terfs)duplicationPathogenicrs397508669GRCh37Chr 7, 117304864: 117304864
240CFTRNM_ 000492.3(CFTR): c.409delC (p.Leu137Serfs)deletionPathogenicrs397508672GRCh37Chr 7, 117171088: 117171088
241CFTRNM_ 000492.3(CFTR): c.4111G> T (p.Glu1371Ter)SNVPathogenicrs397508675GRCh37Chr 7, 117304889: 117304889
242CFTRNM_ 000492.3(CFTR): c.4144C> T (p.Gln1382Ter)SNVPathogenicrs397508684GRCh37Chr 7, 117305520: 117305520
243CFTRNM_ 000492.3(CFTR): c.4147dupA (p.Ile1383Asnfs)duplicationPathogenicrs397508685GRCh37Chr 7, 117305523: 117305523
244CFTRNM_ 000492.3(CFTR): c.4196_ 4197delTC (p.Cys1400Terfs)deletionPathogenicrs397508693GRCh37Chr 7, 117305572: 117305573
245CFTRNM_ 000492.3(CFTR): c.4231C> T (p.Gln1411Ter)SNVPathogenicrs397508701GRCh37Chr 7, 117305607: 117305607
246CFTRNM_ 000492.3(CFTR): c.4234C> T (p.Gln1412Ter)SNVPathogenicrs397508702GRCh37Chr 7, 117305610: 117305610
247CFTRNM_ 000492.3(CFTR): c.4242+1G> TSNVPathogenicrs372227120GRCh37Chr 7, 117305619: 117305619
248CFTRNM_ 000492.3(CFTR): c.4251delA (p.Glu1418Argfs)deletionPathogenicrs397508706GRCh37Chr 7, 117306970: 117306970
249CFTRNM_ 000492.3(CFTR): c.4252G> T (p.Glu1418Ter)SNVLikely pathogenicrs397508707GRCh37Chr 7, 117306971: 117306971
250CFTRNM_ 000492.3(CFTR): c.4426C> T (p.Gln1476Ter)SNVPathogenicrs374705585GRCh37Chr 7, 117307145: 117307145
251CFTRNM_ 000492.3(CFTR): c.442delA (p.Ile148Leufs)deletionPathogenicrs121908770GRCh37Chr 7, 117171121: 117171121
252CFTRNM_ 000492.3(CFTR): c.49_ 50dupTT (p.Trp19Alafs)duplicationPathogenicrs397508739GRCh37Chr 7, 117120197: 117120198
253CFTRNM_ 000492.3(CFTR): c.50delT (p.Phe17Serfs)deletionPathogenicrs397508742GRCh37Chr 7, 117120198: 117120198
254CFTRNM_ 000492.3(CFTR): c.53+1G> TSNVPathogenicrs397508746GRCh37Chr 7, 117120202: 117120202
255CFTRNM_ 000492.3(CFTR): c.531delT (p.Ile177Metfs)deletionPathogenicrs121908771GRCh37Chr 7, 117174371: 117174371
256CFTRNM_ 000492.3(CFTR): c.543_ 546delTAGT (p.Leu183Phefs)deletionPathogenicrs397508750GRCh37Chr 7, 117174383: 117174386
257CFTRNM_ 000492.3(CFTR): c.577G> T (p.Glu193Ter)SNVPathogenicrs397508759GRCh37Chr 7, 117174417: 117174417
258CFTRNM_ 000492.3(CFTR): c.579+3A> GSNVPathogenicrs397508761GRCh37Chr 7, 117174422: 117174422
259CFTRNM_ 000492.3(CFTR): c.579+5G> ASNVPathogenicrs78440224GRCh37Chr 7, 117174424: 117174424
260CFTRNM_ 000492.3(CFTR): c.580-1G> TSNVPathogenicrs121908793GRCh37Chr 7, 117175301: 117175301
261CFTRNM_ 000492.3(CFTR): c.595C> T (p.His199Tyr)SNVPathogenicrs121908802GRCh37Chr 7, 117175317: 117175317
262CFTRNM_ 000492.3(CFTR): c.613C> T (p.Pro205Ser)SNVPathogenicrs121908803GRCh37Chr 7, 117175335: 117175335
263CFTRNM_ 000492.3(CFTR): c.658C> T (p.Gln220Ter)SNVPathogenicrs397508778GRCh37Chr 7, 117175380: 117175380
264CFTRNM_ 000492.3(CFTR): c.680T> G (p.Leu227Arg)SNVPathogenicrs397508782GRCh37Chr 7, 117175402: 117175402
265CFTRNM_ 000492.3(CFTR): c.695T> A (p.Val232Asp)SNVLikely pathogenicrs397508783GRCh37Chr 7, 117175417: 117175417
266CFTRNM_ 000492.3(CFTR): c.743+1G> ASNVPathogenicrs397508791GRCh37Chr 7, 117175466: 117175466
267CFTRNM_ 000492.3(CFTR): c.743+1G> CSNVLikely pathogenicrs397508791GRCh37Chr 7, 117175466: 117175466
268CFTRNM_ 000492.3(CFTR): c.79G> T (p.Gly27Ter)SNVPathogenicrs397508796GRCh37Chr 7, 117144332: 117144332
269CFTRNM_ 000492.3(CFTR): c.828C> A (p.Cys276Ter)SNVPathogenicrs397508799GRCh37Chr 7, 117176686: 117176686
270CFTRNM_ 000492.3(CFTR): c.861_ 865delCTTAA (p.Asn287Lysfs)deletionPathogenicrs397508805GRCh37Chr 7, 117176719: 117176723
271CFTRNM_ 000492.3(CFTR): c.987delA (p.Gly330Glufs)deletionPathogenicrs397508824GRCh37Chr 7, 117180271: 117180271
272CFTRNM_ 000492.3(CFTR): c.1647T> G (p.Ser549Arg)SNVPathogenic, drug responsers121909005GRCh37Chr 7, 117227855: 117227855
273CFTRNM_ 000492.3: c.1679+1.6kbA> Gundetermined variantPathogenic
274CFTRNM_ 000492.3(CFTR): c.2453delT (p.Leu818Trpfs)deletionPathogenicrs397515498GRCh37Chr 7, 117232674: 117232674
275CFTRNM_ 000492.3(CFTR): c.3964-78_ 4242+577deldeletionPathogenicGRCh38Chr 7, 117664610: 117666141
276CFTRNG_ 016465.4: g.37530_ 58609deldeletionPathogenic
277CFTRNM_ 000492.3(CFTR): c.1521_ 1523delCTT (p.Phe508delPhe)deletionPathogenicrs113993960GRCh37Chr 7, 117199646: 117199648
278CFTRNM_ 000492.3(CFTR): c.1519_ 1521delATC (p.Ile507del)deletionPathogenicrs121908745GRCh37Chr 7, 117199644: 117199646
279CFTRNM_ 000492.3(CFTR): c.1477C> T (p.Gln493Ter)SNVPathogenicrs77101217GRCh37Chr 7, 117199602: 117199602
280CFTRNM_ 000492.3(CFTR): c.328G> C (p.Asp110His)SNVPathogenicrs113993958GRCh37Chr 7, 117171007: 117171007
281CFTRNM_ 000492.3(CFTR): c.1040G> C (p.Arg347Pro)SNVPathogenicrs77932196GRCh37Chr 7, 117180324: 117180324
282CFTRNM_ 000492.3(CFTR): c.1364C> A (p.Ala455Glu)SNVPathogenicrs74551128GRCh37Chr 7, 117188849: 117188849
283CFTRNM_ 000492.3(CFTR): c.1585-1G> ASNVPathogenicrs76713772GRCh37Chr 7, 117227792: 117227792
284CFTRNM_ 000492.3(CFTR): c.1679G> C (p.Arg560Thr)SNVPathogenicrs80055610GRCh37Chr 7, 117227887: 117227887
285CFTRNM_ 000492.3(CFTR): c.1687T> A (p.Tyr563Asn)SNVPathogenicrs121909006GRCh37Chr 7, 117230414: 117230414
286CFTRNM_ 000492.3(CFTR): c.1624G> T (p.Gly542Ter)SNVPathogenicrs113993959GRCh37Chr 7, 117227832: 117227832
287CFTRNM_ 000492.3(CFTR): c.1646G> A (p.Ser549Asn)SNVPathogenic, drug responsers121908755GRCh37Chr 7, 117227854: 117227854
288CFTRNM_ 000492.3(CFTR): c.1646G> T (p.Ser549Ile)SNVPathogenicrs121908755GRCh37Chr 7, 117227854: 117227854
289CFTRNM_ 000492.3(CFTR): c.1721C> A (p.Pro574His)SNVPathogenic/ Likely pathogenicrs121908758GRCh37Chr 7, 117230448: 117230448
290CFTRNM_ 000492.3(CFTR): c.1652G> A (p.Gly551Asp)SNVPathogenicrs75527207GRCh37Chr 7, 117227860: 117227860
291CFTRNM_ 000492.3(CFTR): c.1657C> T (p.Arg553Ter)SNVPathogenicrs74597325GRCh37Chr 7, 117227865: 117227865
292CFTRNM_ 000492.3(CFTR): c.1675G> A (p.Ala559Thr)SNVPathogenicrs75549581GRCh37Chr 7, 117227883: 117227883
293CFTRNM_ 000492.3(CFTR): c.3659delC (p.Thr1220Lysfs)deletionPathogenicrs121908811GRCh37Chr 7, 117267766: 117267766
294CFTRNM_ 000492.3(CFTR): c.3764C> A (p.Ser1255Ter)SNVPathogenicrs76649725GRCh38Chr 7, 117642484: 117642484
295CFTRNM_ 000492.3(CFTR): c.2538G> A (p.Trp846Ter)SNVPathogenicrs267606722GRCh37Chr 7, 117235031: 117235031
296CFTRNM_ 000492.3(CFTR): c.2738A> G (p.Tyr913Cys)SNVPathogenicrs121909008GRCh37Chr 7, 117243666: 117243666
297CFTRNM_ 000492.3(CFTR): c.3846G> A (p.Trp1282Ter)SNVPathogenicrs77010898GRCh37Chr 7, 117282620: 117282620
298CFTRNM_ 000492.3(CFTR): c.1373G> T (p.Gly458Val)SNVPathogenicrs121909009GRCh37Chr 7, 117188858: 117188858
299CFTRNM_ 000492.3(CFTR): c.3947G> A (p.Trp1316Ter)SNVPathogenicrs121909010GRCh37Chr 7, 117292969: 117292969
300CFTRNM_ 000492.3(CFTR): c.1021_ 1022dupTC (p.Phe342Hisfs)duplicationPathogenicrs387906360GRCh37Chr 7, 117180305: 117180306
301CFTRNM_ 000492.3(CFTR): c.1081delT (p.Trp361Glyfs)deletionPathogenicrs387906361GRCh37Chr 7, 117180365: 117180365
302CFTRNM_ 000492.3(CFTR): c.3909C> G (p.Asn1303Lys)SNVPathogenicrs80034486GRCh37Chr 7, 117292931: 117292931
303CFTRNM_ 000492.3(CFTR): c.3484C> T (p.Arg1162Ter)SNVPathogenicrs74767530GRCh37Chr 7, 117267591: 117267591
304CFTRNM_ 000492.3(CFTR): c.3717+4A> GSNVPathogenicrs387906362GRCh37Chr 7, 117267828: 117267828
305CFTRNM_ 000492.3(CFTR): c.1000C> T (p.Arg334Trp)SNVPathogenicrs121909011GRCh37Chr 7, 117180284: 117180284
306CFTRNM_ 000492.3(CFTR): c.1545_ 1546delTA (p.Tyr515Terfs)deletionPathogenicrs121908776GRCh37Chr 7, 117199670: 117199671
307CFTRNM_ 000492.3(CFTR): c.2551C> T (p.Arg851Ter)SNVPathogenicrs121909012GRCh37Chr 7, 117235044: 117235044
308CFTRNM_ 000492.3(CFTR): c.1651G> A (p.Gly551Ser)SNVPathogenic/ Likely pathogenic, drug responsers121909013GRCh37Chr 7, 117227859: 117227859
309CFTRNM_ 000492.3(CFTR): c.254G> A (p.Gly85Glu)SNVPathogenicrs75961395GRCh37Chr 7, 117149177: 117149177
310CFTRNM_ 000492.3(CFTR): c.3472C> T (p.Arg1158Ter)SNVPathogenicrs79850223GRCh37Chr 7, 117267579: 117267579
311CFTRNM_ 000492.3(CFTR): c.720_ 741del22 (p.Gly241Glufs)deletionPathogenicrs121908804GRCh37Chr 7, 117175442: 117175463
312CFTRNM_ 000492.3(CFTR): c.424delA (p.Ile142Phefs)deletionPathogenicrs387906363GRCh37Chr 7, 117171103: 117171103
313CFTRNM_ 000492.3(CFTR): c.429delT (p.Phe143Leufs)deletionPathogenicrs387906364GRCh37Chr 7, 117171108: 117171108
314CFTRNM_ 000492.3(CFTR): c.2737_ 2738insG (p.Tyr913Terfs)insertionPathogenicrs121908788GRCh37Chr 7, 117243665: 117243666
315CFTRNM_ 000492.3(CFTR): c.1558G> T (p.Val520Phe)SNVPathogenicrs77646904GRCh37Chr 7, 117199683: 117199683
316CFTRNM_ 000492.3(CFTR): c.1572C> A (p.Cys524Ter)SNVPathogenicrs121908754GRCh37Chr 7, 117199697: 117199697
317CFTRNM_ 000492.3(CFTR): c.3873G> C (p.Gln1291His)SNVPathogenicrs121909015GRCh37Chr 7, 117282647: 117282647
318CFTRNM_ 000492.3(CFTR): c.933C> G (p.Phe311Leu)SNVPathogenicrs121909016GRCh37Chr 7, 117180217: 117180217
319CFTRNM_ 000492.3(CFTR): c.1093_ 1094delCT (p.Leu365Trpfs)deletionPathogenicrs387906365GRCh37Chr 7, 117180377: 117180378
320CFTRNM_ 000492.3(CFTR): c.1475C> T (p.Ser492Phe)SNVPathogenicrs121909017GRCh37Chr 7, 117199600: 117199600
321CFTRNM_ 000492.3(CFTR): c.1679G> A (p.Arg560Lys)SNVPathogenicrs80055610GRCh37Chr 7, 117227887: 117227887
322CFTRNM_ 000492.3(CFTR): c.2479G> T (p.Glu827Ter)SNVPathogenicrs121909018GRCh37Chr 7, 117232700: 117232700
323CFTRNM_ 000492.3(CFTR): c.3197G> A (p.Arg1066His)SNVPathogenicrs121909019GRCh37Chr 7, 117251692: 117251692
324CFTRNM_ 000492.3(CFTR): c.3873+1G> ASNVPathogenicrs143570767GRCh37Chr 7, 117282648: 117282648
325CFTRNM_ 000492.3(CFTR): c.3184_ 3188dupCTATG (p.Trp1063Cysfs)duplicationPathogenicrs387906366GRCh37Chr 7, 117251679: 117251683
326CFTRNM_ 000492.3(CFTR): c.3196C> T (p.Arg1066Cys)SNVPathogenicrs78194216GRCh37Chr 7, 117251691: 117251691
327CFTRNM_ 000492.3(CFTR): c.948delT (p.Phe316Leufs)deletionPathogenicrs121908744GRCh37Chr 7, 117180232: 117180232
328CFTRNM_ 000492.3: c.3718-2477C> TSNVPathogenicrs75039782GRCh37Chr 7, 117280015: 117280015
329CFTRNM_ 000492.3(CFTR): c.3848G> T (p.Arg1283Met)SNVPathogenicrs77902683GRCh37Chr 7, 117282622: 117282622
330CFTRNM_ 000492.3(CFTR): c.1766+1G> ASNVPathogenicrs121908748GRCh37Chr 7, 117230494: 117230494
331CFTRNM_ 000492.3(CFTR): c.744-14_ 744-3delTGATTGATTTACdeletionPathogenicrs387906367GRCh37Chr 7, 117176588: 117176599
332CFTRNM_ 000492.3(CFTR): c.1040G> T (p.Arg347Leu)SNVPathogenicrs77932196GRCh37Chr 7, 117180324: 117180324
333CFTRNM_ 000492.3(CFTR): c.1046C> T (p.Ala349Val)SNVPathogenicrs121909021GRCh37Chr 7, 117180330: 117180330
334CFTRNM_ 000492.3(CFTR): c.1601C> A (p.Ala534Glu)SNVPathogenicrs387906368GRCh38Chr 7, 117587755: 117587755
335CFTRNM_ 000492.3(CFTR): c.2146A> T (p.Lys716Ter)SNVPathogenicrs121909023GRCh37Chr 7, 117232367: 117232367
336CFTRNM_ 000492.3(CFTR): c.2490+1G> ASNVPathogenicrs141158996GRCh37Chr 7, 117232712: 117232712
337CFTRNM_ 000492.3(CFTR): c.3712C> T (p.Gln1238Ter)SNVPathogenic/ Likely pathogenicrs121908766GRCh37Chr 7, 117267819: 117267819
338CFTRNM_ 000492.3(CFTR): c.3718-1G> ASNVPathogenicrs387906369GRCh37Chr 7, 117282491: 117282491
339CFTRNM_ 000492.3(CFTR): c.3767dupC (p.Leu1258Phefs)duplicationPathogenicrs387906370GRCh38Chr 7, 117642487: 117642487
340CFTRNM_ 000492.3(CFTR): c.171G> A (p.Trp57Ter)SNVPathogenicrs121909025GRCh37Chr 7, 117149094: 117149094
341CFTRNM_ 000492.3(CFTR): c.3937C> T (p.Gln1313Ter)SNVPathogenicrs121909026GRCh37Chr 7, 117292959: 117292959
342CFTRNM_ 000492.3(CFTR): c.274G> A (p.Glu92Lys)SNVPathogenicrs121908751GRCh37Chr 7, 117170953: 117170953
343CFTRNM_ 000492.3(CFTR): c.1040G> A (p.Arg347His)SNVPathogenicrs77932196GRCh37Chr 7, 117180324: 117180324
344CFTRNM_ 000492.3(CFTR): c.271G> A (p.Gly91Arg)SNVPathogenicrs121908750GRCh37Chr 7, 117149194: 117149194
345CFTRNM_ 000492.3(CFTR): c.3857T> C (p.Phe1286Ser)SNVPathogenicrs121909028GRCh37Chr 7, 117282631: 117282631
346CFTRNM_ 000492.3(CFTR): c.2175dupA (p.Glu726Argfs)duplicationPathogenicrs121908787GRCh37Chr 7, 117232396: 117232396
347CFTRNM_ 000492.3(CFTR): c.274G> T (p.Glu92Ter)SNVPathogenicrs121908751GRCh37Chr 7, 117170953: 117170953
348CFTRNM_ 000492.3(CFTR): c.1438G> T (p.Gly480Cys)SNVPathogenicrs79282516GRCh37Chr 7, 117199563: 117199563
349CFTRNM_ 000492.3(CFTR): c.459_ 476del18 (p.Ala155_ Ile160del)deletionPathogenicrs387906371GRCh37Chr 7, 117171138: 117171155
350CFTRNM_ 000492.3(CFTR): c.1210-12_ 1210-6T[5]short repeatrisk factorrs727504486GRCh37Chr 7, 117188683: 117188689
351CFTRNM_ 000492.3(CFTR): c.617T> G (p.Leu206Trp)SNVPathogenicrs121908752GRCh37Chr 7, 117175339: 117175339
352CFTRCFTR, GLN524HISSNVPathogenic
353CFTRNM_ 000492.3(CFTR): c.3763T> C (p.Ser1255Pro)SNVPathogenic/ Likely pathogenic, drug responsers121909041GRCh37Chr 7, 117282537: 117282537
354CFTRNM_ 000492.3(CFTR): c.1013C> T (p.Thr338Ile)SNVPathogenicrs77409459GRCh37Chr 7, 117180297: 117180297
355CFTRNM_ 000492.3(CFTR): c.3266G> A (p.Trp1089Ter)SNVPathogenicrs78802634GRCh37Chr 7, 117251761: 117251761
356CFTRNM_ 000492.3(CFTR): c.326A> G (p.Tyr109Cys)SNVPathogenicrs121909031GRCh37Chr 7, 117171005: 117171005
357CFTRNM_ 000492.3(CFTR): c.1055G> A (p.Arg352Gln)SNVPathogenicrs121908753GRCh37Chr 7, 117180339: 117180339
358CFTRNM_ 000492.3(CFTR): c.273+4A> GSNVPathogenicrs387906374GRCh37Chr 7, 117149200: 117149200
359CFTRNM_ 000492.3(CFTR): c.1654C> T (p.Gln552Ter)SNVPathogenicrs76554633GRCh37Chr 7, 117227862: 117227862
360CFTRNM_ 000492.3(CFTR): c.1943A> T (p.Asp648Val)SNVPathogenicrs121909033GRCh37Chr 7, 117232164: 117232164
361CFTRNM_ 000492.3(CFTR): c.2128A> T (p.Lys710Ter)SNVPathogenicrs75115087GRCh37Chr 7, 117232349: 117232349
362CFTRNM_ 000492.3(CFTR): c.2668C> T (p.Gln890Ter)SNVPathogenicrs79633941GRCh37Chr 7, 117243596: 117243596
363CFTRNM_ 000492.3(CFTR): c.805_ 806delAT (p.Ile269Profs)deletionPathogenicrs121908773GRCh37Chr 7, 117176663: 117176664
364CFTRNM_ 000492.3(CFTR): c.2845C> T (p.His949Tyr)SNVPathogenicrs121909035GRCh37Chr 7, 117243773: 117243773
365CFTRNM_ 000492.3(CFTR): c.3194T> C (p.Leu1065Pro)SNVPathogenicrs121909036GRCh37Chr 7, 117251689: 117251689
366CFTRNM_ 000492.3(CFTR): c.3212A> C (p.Gln1071Pro)SNVPathogenicrs121909037GRCh37Chr 7, 117251707: 117251707
367CFTRNM_ 000492.3(CFTR): c.3254A> G (p.His1085Arg)SNVPathogenic/ Likely pathogenicrs79635528GRCh37Chr 7, 117251749: 117251749
368CFTRNM_ 000492.3(CFTR): c.3611G> A (p.Trp1204Ter)SNVPathogenicrs121908764GRCh37Chr 7, 117267718: 117267718
369CFTRNM_ 000492.3(CFTR): c.1083delG (p.Trp361Cysfs)deletionPathogenicrs387906375GRCh37Chr 7, 117180367: 117180367
370CFTRNM_ 000492.3(CFTR): c.3659C> T (p.Thr1220Ile)SNVPathogenicrs1800123GRCh37Chr 7, 117267766: 117267766
371CFTRNM_ 000492.3(CFTR): c.3700A> G (p.Ile1234Val)SNVPathogenicrs75389940GRCh37Chr 7, 117267807: 117267807
372CFTRNM_ 000492.3(CFTR): c.3746G> A (p.Gly1249Glu)SNVPathogenicrs121909040GRCh37Chr 7, 117282520: 117282520
373CFTRNM_ 000492.3(CFTR): c.3752G> A (p.Ser1251Asn)SNVPathogenic, drug responsers74503330GRCh37Chr 7, 117282526: 117282526
374CFTRNM_ 000492.3(CFTR): c.3907A> C (p.Asn1303His)SNVPathogenicrs121909042GRCh37Chr 7, 117292929: 117292929
375CFTRNM_ 000492.3(CFTR): c.1477_ 1478delCA (p.Gln493Valfs)deletionPathogenicrs121908775GRCh37Chr 7, 117199602: 117199603
376CFTRNM_ 000492.3(CFTR): c.2291delG (p.Arg764Glnfs)deletionPathogenicrs387906376GRCh37Chr 7, 117232512: 117232512
377CFTRNM_ 000492.3(CFTR): c.3161delA (p.His1054Leufs)deletionPathogenicrs387906377GRCh37Chr 7, 117251656: 117251656
378CFTRNM_ 000492.3(CFTR): c.3532_ 3535dupTCAA (p.Thr1179Ilefs)duplicationPathogenicrs387906378GRCh37Chr 7, 117267639: 117267642
379CFTRNM_ 000492.3(CFTR): c.4364C> G (p.Ser1455Ter)SNVPathogenicrs121909043GRCh37Chr 7, 117307083: 117307083
380CFTRNM_ 000492.3(CFTR): c.2988+1G> ASNVPathogenicrs75096551GRCh37Chr 7, 117246808: 117246808
381CFTRNM_ 000492.3(CFTR): c.1658G> A (p.Arg553Gln)SNVPathogenicrs121909044GRCh37Chr 7, 117227866: 117227866
382CFTRNM_ 000492.3(CFTR): c.-102A=SNVPathogenicGRCh37Chr 7, 117120047: 117120047
383CFTRNG_ 016465.3: g.(37526_ 37529)_ (58606_ 58609)deletionPathogenicGRCh37Chr 7, 117138363: 117159446
384CFTRNM_ 000492.3(CFTR): c.3469-20T> CSNVPathogenicrs373002889GRCh37Chr 7, 117267556: 117267556
385CFTRNM_ 000492.3(CFTR): c.2991G> C (p.Leu997Phe)SNVrisk factorrs1800111GRCh37Chr 7, 117250575: 117250575
386CFTRNM_ 000492.3(CFTR): c.3492dupT (p.Lys1165Terfs)duplicationPathogenicrs387906379GRCh37Chr 7, 117267599: 117267599
387CFTRNM_ 000492.3(CFTR): c.3744delA (p.Lys1250Argfs)deletionPathogenicrs121908784GRCh37Chr 7, 117282518: 117282518
388CFTRNM_ 000492.3(CFTR): c.262_ 263delTT (p.Leu88Ilefs)deletionPathogenicrs121908769GRCh37Chr 7, 117149185: 117149186
389CFTRCFTR, HIS1282TERundetermined variantPathogenic
390CFTRCFTR, ALA445GLUundetermined variantPathogenic
391CFTRNM_ 000492.3(CFTR): c.19G> T (p.Glu7Ter)SNVPathogenicrs121909045GRCh37Chr 7, 117120167: 117120167
392CFTRNM_ 000492.3(CFTR): c.860dupA (p.Asn287Lysfs)duplicationPathogenicrs387906380GRCh37Chr 7, 117176718: 117176718
393CFTRNM_ 000492.3(CFTR): c.1682C> A (p.Ala561Glu)SNVPathogenicrs121909047GRCh37Chr 7, 117230409: 117230409

Copy number variations for Cystic Fibrosis from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
12187577116907252117095954DeletionCFTRCystic fibrosis
22187587116907252117095954DeletionCFTRCystic fibrosis
32337648127300000131500000Copy numberL1Cystic fibrosis

Expression for genes affiliated with Cystic Fibrosis

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Cystic Fibrosis patients vs. healthy controls: 35
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1ALDOBaldolase B, fructose-bisphosphateEpithelial Cells+3.080.000

Search GEO for disease gene expression data for Cystic Fibrosis.

Pathways for genes affiliated with Cystic Fibrosis

About this section

GO Terms for genes affiliated with Cystic Fibrosis

About this section

Cellular components related to Cystic Fibrosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular exosomeGO:007006211.0CFTR, CLCA4, DEFB1, DNAJC5, DNASE1, ELANE
2microvillusGO:000590210.9CLCA1, SLC9A3R1, TGFB1
3extracellular regionGO:000557610.9CLCA1, CLCA4, CXCL8, DEFB1, DNASE1, ELANE
4extracellular spaceGO:000561510.8CLCA1, CXCL8, DEFB1, ELANE, PRSS1, S100A8
5secretory granuleGO:003014110.7CLCA1, ELANE, STX1A, TGFB1
6sperm midpieceGO:009722510.4DEFB1, SLC9A3R1

Biological processes related to Cystic Fibrosis according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1acute inflammatory responseGO:000252611.2DEFB1, S100A8
2astrocyte developmentGO:001400211.1S100A8, S100A9
3chemokine productionGO:003260211.1S100A8, S100A9
4chloride transmembrane transportGO:190247611.1CFTR, CLCA1, CLCA4
5chloride transportGO:000682111.1CFTR, CLCA1, CLCA4
6neutrophil aggregationGO:007048811.1S100A8, S100A9
7antimicrobial humoral responseGO:001973011.1DEFB1, ELANE, S100A8, S100A9
8chemotaxisGO:000693511.1CXCL8, DEFB1, S100A8, S100A9
9defense response to fungusGO:005083211.1ELANE, S100A8, S100A9
10leukocyte migration involved in inflammatory responseGO:000252311.1ELANE, S100A8, S100A9
11neutrophil chemotaxisGO:003059311.1CXCL8, S100A8, S100A9
12defense response to bacteriumGO:004274211.1DEFB1, ELANE, S100A8, S100A9
13peptidyl-cysteine S-nitrosylationGO:001811910.9S100A8, S100A9
14neutrophil degranulationGO:004331210.8DNAJC5, ELANE, FCGR2A, S100A8, S100A9
15positive regulation of intrinsic apoptotic signaling pathwayGO:200124410.6S100A8, S100A9, SLC9A3R1
16positive regulation of peptide secretionGO:000279310.5S100A8, S100A9
17sequestering of zinc ionGO:003211910.4S100A8, S100A9

Molecular functions related to Cystic Fibrosis according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1arachidonic acid bindingGO:005054411.0S100A8, S100A9
2ATP-dependent protein bindingGO:004300811.0DNAJC5, STX1A
3chloride channel inhibitor activityGO:001986911.0CFTR, STX1A
4chloride channel regulator activityGO:001708111.0CFTR, SLC9A3R1
5chloride channel activityGO:000525411.0CFTR, CLCA1, CLCA4
6intracellular calcium activated chloride channel activityGO:000522911.0CLCA1, CLCA4
7glycoprotein bindingGO:000194811.0DNAJC5, STX1A, TGFB1
8protein N-terminus bindingGO:004748510.7DCTN4, STX1A, TGFB1
9RAGE receptor bindingGO:005078610.5S100A8, S100A9
10Toll-like receptor 4 bindingGO:003566210.4S100A8, S100A9

Sources for Cystic Fibrosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet